



09/833041

~~CoFC~~

PATENT
Customer No. 22,852
Attorney Docket No. 6832.0016

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re U.S. Patent No.: 6,994,857)
Inventors:)
Craig A. Rosen and William A. Haseltine)
Issue Date.: February 7, 2006)
For: ALBUMIN FUSION PROTEINS)

Certificate
MAR 10 2006
of Correction

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

REQUEST FOR CERTIFICATE OF CORRECTION

Pursuant to 35 U.S.C. §§ 254 and 255, and 37 C.F.R. §§ 1.322 and 1.323, this is a request for a Certificate of Correction in the above-identified patent. Some of the mistakes identified in the appended Form occurred through the fault of the Patent Office, as clearly disclosed by the records of the application which matured into this patent.

For example, the priority claims to Provisional Application Nos. 60/256,931, filed December 21, 2000; 60/199,384, filed April 25, 2000; and 60/229,358, filed April 12, 2000, were deleted in an Amendment filed June 3, 2004, and a Corrected Filing Receipt reflecting the change was mailed by the PTO on August 11, 2004. However, the issued patent was printed with the priority claims in the title page under item (60).
03/08/2006 SZENDIEI 00000066 6994857
01 FF 1011 100.00 0P

Furthermore, Applicants cited the Hershfield reference once, and also the Hochuli and Nilsson (1997) references in an Information Disclosure Statement filed May

MAR 13 2006

18, 2004. The initialized PTO 1449 form was returned to Applicants with the Notice of Allowability dated July 20, 2004. However, the patent issued listing the Hershfield reference twice and omitting the Hochuli and Nilsson (1997) references. The Certificate of Correction corrects these errors.

Additionally, none of the corrections made to SEQ ID NOs in the specification by an Amendment filed on May 18, 2004, were incorporated into the issued patent. Similarly, the issued patent reflects the original Sequence Listing filed rather than the Substitute Sequence Listing submitted on May 18, 2004. The Sequence Listing in the attached Certificate of Correction is identical to the Substitute Sequence Listing filed on May 18, 2004, and is also identical to the computer readable copy of the Substitute Sequence Listing also submitted on May 18, 2004. Thus, the correction contains no new matter.

Claims 1(c), 1(i), and claim 22 contain clerical or typographical errors of minor character that are also the result of the Patent Office. Other mistakes identified in the appended Form are of a clerical or typographical nature, or of minor character, and resulted from an error made in good faith by Patentees.

A check in the amount of \$100 (the fee set forth in 37 C.F.R. § 1.20(a)) is attached. Should a check not be appended or should any additional fees be needed, authorization is hereby given to charge any fees due in connection with the filing of this request to Deposit Account No. 06-0916.

Two (2) copies of PTO Form 1050 are appended. The complete Certificate of Correction involves forty-six (46) pages. Issuance of the Certificate of Correction containing the correction is earnestly requested.

MAR 13 2006

Please charge any required fees not included herewith to our deposit account

06-0916.

Respectfully submitted,

FINNEGAN, HENDERSON, FARABOW,
GARRETT & DUNNER, L.L.P.

Dated: March 7, 2006

By: Charles E. Van Horn
Charles E. Van Horn
Reg. No. 40,266

MAR 13 2006

UNITED STATES PATENT AND TRADEMARK OFFICE
CERTIFICATE OF CORRECTION

PATENT NO. 6,994,857

Page 1 of 46

APPLICATION NO.: 09/833,041

ISSUE DATE: February 7, 2006

INVENTOR(S): Craig A. Rosen, William A. Haseltine

It is hereby certified that an error or errors appear in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

Under item (60) (Related U.S. Application Data) of the title page, delete the text beginning with "Provisional application No. 60/229,358" to and ending "provisional application No. 60/256,931, filed on Dec. 1, 2000."

Under item (57) (ABSTRACT) of the title page, "disordrs" should read --disorders--.

On page 7, column 2, in the 8th reference, delete the text beginning with "Hershfield, M.S., et al.," to and ending "7185-7189 (1991)" and insert -- Hochuli, E., "Interferon Immunogenicity: Technical Evaluation of Interferon- α 2a," *Journal of Interferon and Cytokine Research* 17:S15-S21 (1997). --

On page 10, column 2, after the 9th reference (Nilsson, J., et al.), insert -- Nilsson, J. et al., "Heat-Mediated Activation of Affinity-Immobilized Taq DNA Polymerase," *BioTechniques* 22:744-751 (1997). --

In the Specification:

Col. 25 (Table 1), row HLDOU18, column Exemplary Identifier, "SEQ ID NO:73" should read -- SEQ ID NO:74 --.

Col. 27 (Table 1), row HWACB86, column Exemplary Identifier, "SEQ ID NO:74" should read -- SEQ ID NO:75 --.

Col. 27 (Table 1), row HCEGG08, column Exemplary Identifier, "SEQ ID NO:75" should read -- SEQ ID NO:76 --.

Col. 29 (Table 1), row HWHGZ51, column Exemplary Identifier, "SEQ ID NO:76" should read -- SEQ ID NO:77 --.

MAILING ADDRESS OF SENDER

U.S. Patent No. 6,994,857

Finnegan, Henderson, Farabow,
Garrett & Dunner, L.L.P.
901 New York Avenue, N.W.
Washington, D.C. 20001-4413

MAR 13 2006

Col. 29 (Table 1), row HDTAI21, column Exemplary Identifier, "SEQ ID NO:77" should read -- SEQ ID NO:78 --.

Col. 29 (Table 1), row HCNCA73, column Exemplary Identifier, "SEQ ID NO:78" should read -- SEQ ID NO:79 --.

Col. 29 (Table 1), row HNHFE71, column Exemplary Identifier, "SEQ ID NO:79" should read -- SEQ ID NO:80 --.

Col. 62, lines 38-39, "(SEQ ID NO:36)" should read -- (SEQ ID NO:72) --.

Col. 215, line 8, "(SEQ ID NO:36)" should read -- (SEQ ID NO:81) --.

Col. 236, line 42, "(SEQ ID NO: 37)" should read -- (SEQ ID NO:82) --.

Col. 237, line 47, "(SEQ ID NO:38)" should read -- (SEQ ID NO:83) --.

Col. 237, lines 53-54, "(SEQ ID NO:39)" should read -- (SEQ ID NO:84) --.

Col. 237, line 63, "(SEQ ID NO:40)" should read -- (SEQ ID NO:85) --.

Col. 240, line 55, "(SEQ ID NO:41)" should read -- (SEQ ID NO:86) --.

Col. 240, line 58, "(SEQ ID NO:42)" should read -- (SEQ ID NO:87) --.

Col. 243, line 9, "(SEQ ID NO:43)" should read -- (SEQ ID NO:88) --.

Col. 243, line 14, "(SEQ ID NO:44)" should read -- (SEQ ID NO:89) --.

Col. 243, lines 17-18, "(SEQ ID NO:39)" should read -- (SEQ ID NO:84) --.

Col. 243, line 28, "(SEQ ID NO:45)" should read -- (SEQ ID NO:90) --.

In the Sequence Listing:

Delete the Sequence Listing beginning in Col. 263, beginning with the text "<160> NUMBER OF SEQ ID NOS: 79" to and ending "Pro Thr Ser Cys Ser Arg Cys"
165

in Col. 313 and insert the following Sequence Listing:

-- <160> NUMBER OF SEQ ID NOS: 90

<210> 1

<211> 23

<212> DNA

<213> Artificial Sequence

MAILING ADDRESS OF SENDER

U.S. Patent No. 6,994,857

Finnegan, Henderson, Farabow,
Garrett & Dunner, L.L.P.
901 New York Avenue, N.W.
Washington, D.C. 20001-4413

MAR 13 2006

<220>
 <221> primer_bind
 <223> primer useful to clone human growth hormone cDNA

 <400> 1
 cccaagaatt cccttatcca ggc 23

 <210> 2
 <211> 33
 <212> DNA
 <213> Artificial Sequence
 <220>
 <221> primer_bind
 <223> primer useful to clone human growth hormone cDNA

 <400> 2
 gggaagctta gaagccacag gatccctcca cag 33

 <210> 3
 <211> 16
 <212> DNA
 <213> Artificial Sequence
 <220>
 <221> misc_structure
 <223> synthetic oligonucleotide used to join DNA fragments
 with non-cohesive ends.

 <400> 3
 gataaagatt cccaac 16

 <210> 4
 <211> 17
 <212> DNA
 <213> Artificial Sequence
 <220>
 <221> misc_structure
 <223> synthetic oligonucleotide used to join DNA fragments
 with non-cohesive ends.

 <400> 4
 aattgttggg aatcttt 17

 <210> 5
 <211> 17
 <212> DNA
 <213> Artificial Sequence
 <220>
 <221> misc_structure

MAILING ADDRESS OF SENDER

U.S. Patent No. 6,994,857

Finnegan, Henderson, Farabow,
 Garrett & Dunner, L.L.P.
 901 New York Avenue, N.W.
 Washington, D.C. 20001-4413

<223> synthetic oligonucleotide used to join DNA fragments with non-cohesive ends.

<400> 5

ttaggcttat tcccaac

17

<210> 6

<211> 18

<212> DNA

<213> Artificial Sequence

<220>

<221> misc_structure

<223> synthetic oligonucleotide used to join DNA fragments with non-cohesive ends.

<400> 6

aattgttggg aataagcc

18

<210> 7

<211> 24

<212> PRT

<213> Artificial Sequence

<220>

<221> SITE

<222> 1) .. (19)

<223> invertase leader sequence

<220>

<221> SITE

<222> 20) .. (24)

<223> first 5 amino acids of mature human serum albumin

<400> 7

Met Leu Leu Gln Ala Phe Leu Phe Leu Leu Ala Gly Phe Ala Ala Lys

1

5

10

15

Ile Ser Ala Asp Ala His Lys Ser

20

<210> 8

<211> 21

<212> DNA

<213> Artificial Sequence

<220>

<221> misc_structure

<223> synthetic oligonucleotide used to join DNA fragments with non-cohesive ends.

<400> 8

gagatgcaca cctgagttag g

21

MAILING ADDRESS OF SENDER

U.S. Patent No. 6,994,857

Finnegan, Henderson, Farabow,
Garrett & Dunner, L.L.P.
901 New York Avenue, N.W.
Washington, D.C. 20001-4413

MAR 18 2006

<p> <210> 9 <211> 27 <212> DNA <213> Artificial Sequence <220> <221> misc_structure <223> synthetic oligonucleotide used to join DNA fragments with non-cohesive ends. <400> 9 gatcctgtgg cttcgatgca cacaaga </p>	27
<p> <210> 10 <211> 24 <212> DNA <213> Artificial Sequence <220> <221> misc_structure <223> synthetic oligonucleotide used to join DNA fragments with non-cohesive ends. <400> 10 ctcttggtg catcgaagcc acag </p>	24
<p> <210> 11 <211> 30 <212> DNA <213> Artificial Sequence <220> <221> misc_structure <223> synthetic oligonucleotide used to join DNA fragments with non-cohesive ends. <400> 11 tgtggaagag cctcagaatt tattcccaac </p>	30
<p> <210> 12 <211> 31 <212> DNA <213> Artificial Sequence <220> <221> misc_structure <223> synthetic oligonucleotide used to join DNA fragments with non-cohesive ends. <400> 12 aattggtggg aataaattct gaggctcttc c </p>	31

MAILING ADDRESS OF SENDER

U.S. Patent No. 6,994,857

Finnegan, Henderson, Farabow,
Garrett & Dunner, L.L.P.
901 New York Avenue, N.W.
Washington, D.C. 20001-4413

MAY 18 2006

<210> 13
 <211> 47
 <212> DNA
 <213> Artificial Sequence
 <220>
 <221> misc_structure
 <223> synthetic oligonucleotide used to join DNA
 fragments with non-cohesive ends.

<400> 13
 ttaggcttag gtggcgggtg atccggcggg ggtggatctt tcccaac 47

<210> 14
 <211> 48
 <212> DNA
 <213> Artificial Sequence
 <220>
 <221> misc_structure
 <223> synthetic oligonucleotide used to join DNA
 fragments with non-cohesive ends.

<400> 14
 aattgttggg aaagatccac caccgccgga tccaccgcca cctaagcc 48

<210> 15
 <211> 62
 <212> DNA
 <213> Artificial Sequence
 <220>
 <221> misc_structure
 <223> synthetic oligonucleotide used to join DNA
 fragments with non-cohesive ends.

<400> 15
 ttaggcttag gcggtggtg atctggtggc ggcggatctg gtggcgggtg atccttccca 60
 ac 62

<210> 16
 <211> 63
 <212> DNA
 <213> Artificial Sequence
 <220>
 <221> misc_structure
 <223> synthetic oligonucleotide used to join DNA
 fragments with non-cohesive ends.

<400> 16
 aattgttggg aaggatccac cgccaccaga tccgccgcca ccagatccac caccgcctaa 60

MAILING ADDRESS OF SENDER

U.S. Patent No. 6,994,857

Finnegan, Henderson, Farabow,
 Garrett & Dunner, L.L.P.
 901 New York Avenue, N.W.
 Washington, D.C. 20001-4413

MAR 13 2006

gcc	63
<210> 17	
<211> 1782	
<212> DNA	
<213> Homo sapiens	
<220>	
<221> CDS	
<222> (1) .. (1755)	
<400> 17	
gat gca cac aag agt gag gtt gct cat cgg ttt aaa gat ttg gga gaa	48
Asp Ala His Lys Ser Glu Val Ala His Arg Phe Lys Asp Leu Gly Glu	
1 5 10 15	
gaa aat ttc aaa gcc ttg gtg ttg att gcc ttt gct cag tat ctt cag	96
Glu Asn Phe Lys Ala Leu Val Leu Ile Ala Phe Ala Gln Tyr Leu Gln	
20 25 30	
cag tgt cca ttt gaa gat cat gta aaa tta gtg aat gaa gta act gaa	144
Gln Cys Pro Phe Glu Asp His Val Lys Leu Val Asn Glu Val Thr Glu	
35 40 45	
ttt gca aaa aca tgt gtt gct gat gag tca gct gaa aat tgt gac aaa	192
Phe Ala Lys Thr Cys Val Ala Asp Glu Ser Ala Glu Asn Cys Asp Lys	
50 55 60	
tca ctt cat acc ctt ttt gga gac aaa tta tgc aca gtt gca act ctt	240
Ser Leu His Thr Leu Phe Gly Asp Lys Leu Cys Thr Val Ala Thr Leu	
65 70 75 80	
cgt gaa acc tat ggt gaa atg gct gac tgc tgt gca aaa caa gaa cct	288
Arg Glu Thr Tyr Gly Glu Met Ala Asp Cys Cys Ala Lys Gln Glu Pro	
85 90 95	
gag aga aat gaa tgc ttc ttg caa cac aaa gat gac aac cca aac ctc	336
Glu Arg Asn Glu Cys Phe Leu Gln His Lys Asp Asp Asn Pro Asn Leu	
100 105 110	
ccc cga ttg gtg aga cca gag gtt gat gtg atg tgc act gct ttt cat	384
Pro Arg Leu Val Arg Pro Glu Val Asp Val Met Cys Thr Ala Phe His	
115 120 125	
gac aat gaa gag aca ttt ttg aaa aaa tac tta tat gaa att gcc aga	432
Asp Asn Glu Glu Thr Phe Leu Lys Lys Tyr Leu Tyr Glu Ile Ala Arg	
130 135 140	
aga cat cct tac ttt tat gcc ccg gaa ctc ctt ttc ttt gct aaa agg	480
Arg His Pro Tyr Phe Tyr Ala Pro Glu Leu Leu Phe Phe Ala Lys Arg	
145 150 155 160	

MAILING ADDRESS OF SENDER

U.S. Patent No. 6,994,857

Finnegan, Henderson, Farabow,
Garrett & Dunner, L.L.P.
901 New York Avenue, N.W.
Washington, D.C. 20001-4413

MAR 13 2006

tat	aaa	gct	gct	ttt	aca	gaa	tgt	tgc	caa	gct	gct	gat	aaa	gct	gcc	528
Tyr	Lys	Ala	Ala	Phe	Thr	Glu	Cys	Cys	Gln	Ala	Ala	Asp	Lys	Ala	Ala	
				165					170						175	
tgc	ctg	ttg	cca	aag	ctc	gat	gaa	ctt	cgg	gat	gaa	ggg	aag	gct	tcg	576
Cys	Leu	Leu	Pro	Lys	Leu	Asp	Glu	Leu	Arg	Asp	Glu	Gly	Lys	Ala	Ser	
			180					185					190			
tct	gcc	aaa	cag	aga	ctc	aaa	tgt	gcc	agt	ctc	caa	aaa	ttt	gga	gaa	624
Ser	Ala	Lys	Gln	Arg	Leu	Lys	Cys	Ala	Ser	Leu	Gln	Lys	Phe	Gly	Glu	
		195					200					205				
aga	gct	ttc	aaa	gca	tgg	gca	gtg	gct	cgc	ctg	agc	cag	aga	ttt	ccc	672
Arg	Ala	Phe	Lys	Ala	Trp	Ala	Val	Ala	Arg	Leu	Ser	Gln	Arg	Phe	Pro	
	210					215					220					
aaa	gct	gag	ttt	gca	gaa	ggt	tcc	aag	tta	gtg	aca	gat	ctt	acc	aaa	720
Lys	Ala	Glu	Phe	Ala	Glu	Val	Ser	Lys	Leu	Val	Thr	Asp	Leu	Thr	Lys	
225					230					235					240	
gtc	cac	acg	gaa	tgc	tgc	cat	gga	gat	ctg	ctt	gaa	tgt	gct	gat	gac	768
Val	His	Thr	Glu	Cys	Cys	His	Gly	Asp	Leu	Leu	Glu	Cys	Ala	Asp	Asp	
			245					250						255		
agg	gcg	gac	ctt	gcc	aag	tat	atc	tgt	gaa	aat	cag	gat	tcg	atc	tcc	816
Arg	Ala	Asp	Leu	Ala	Lys	Tyr	Ile	Cys	Glu	Asn	Gln	Asp	Ser	Ile	Ser	
			260					265					270			
agt	aaa	ctg	aag	gaa	tgc	tgt	gaa	aaa	cct	ctg	ttg	gaa	aaa	tcc	cac	864
Ser	Lys	Leu	Lys	Glu	Cys	Cys	Glu	Lys	Pro	Leu	Leu	Glu	Lys	Ser	His	
		275					280					285				
tgc	att	gcc	gaa	gtg	gaa	aat	gat	gag	atg	cct	gct	gac	ttg	cct	tca	912
Cys	Ile	Ala	Glu	Val	Glu	Asn	Asp	Glu	Met	Pro	Ala	Asp	Leu	Pro	Ser	
	290					295					300					
tta	gct	gct	gat	ttt	gtt	gaa	agt	aag	gat	gtt	tgc	aaa	aac	tat	gct	960
Leu	Ala	Ala	Asp	Phe	Val	Glu	Ser	Lys	Asp	Val	Cys	Lys	Asn	Tyr	Ala	
305					310					315					320	
gag	gca	aag	gat	gtc	ttc	ctg	ggc	atg	ttt	ttg	tat	gaa	tat	gca	aga	1008
Glu	Ala	Lys	Asp	Val	Phe	Leu	Gly	Met	Phe	Leu	Tyr	Glu	Tyr	Ala	Arg	
				325				330						335		
agg	cat	cct	gat	tac	tct	gtc	gtg	ctg	ctg	ctg	aga	ctt	gcc	aag	aca	1056
Arg	His	Pro	Asp	Tyr	Ser	Val	Val	Leu	Leu	Leu	Arg	Leu	Ala	Lys	Thr	
			340					345					350			
tat	gaa	acc	act	cta	gag	aag	tgc	tgt	gcc	gct	gca	gat	cct	cat	gaa	1104
Tyr	Glu	Thr	Thr	Leu	Glu	Lys	Cys	Cys	Ala	Ala	Ala	Asp	Pro	His	Glu	
		355					360					365				

MAILING ADDRESS OF SENDER

U.S. Patent No. 6,994,857

Finnegan, Henderson, Farabow,
Garrett & Dunner, L.L.P.
901 New York Avenue, N.W.
Washington, D.C. 20001-4413

MAR 13 2006

tgc tat gcc aaa gtg ttc gat gaa ttt aaa cct ctt gtg gaa gag cct	1152
Cys Tyr Ala Lys Val Phe Asp Glu Phe Lys Pro Leu Val Glu Glu Pro	
370 375 380	
cag aat tta atc aaa caa aac tgt gag ctt ttt gag cag ctt gga gag	1200
Gln Asn Leu Ile Lys Gln Asn Cys Glu Leu Phe Glu Gln Leu Gly Glu	
385 390 395 400	
tac aaa ttc cag aat gcg cta tta gtt cgt tac acc aag aaa gta ccc	1248
Tyr Lys Phe Gln Asn Ala Leu Leu Val Arg Tyr Thr Lys Lys Val Pro	
405 410 415	
caa gtg tca act cca act ctt gta gag gtc tca aga aac cta gga aaa	1296
Gln Val Ser Thr Pro Thr Leu Val Glu Val Ser Arg Asn Leu Gly Lys	
420 425 430	
gtg ggc agc aaa tgt tgt aaa cat cct gaa gca aaa aga atg ccc tgt	1344
Val Gly Ser Lys Cys Cys Lys His Pro Glu Ala Lys Arg Met Pro Cys	
435 440 445	
gca gaa gac tat cta tcc gtg gtc ctg aac cag tta tgt gtg ttg cat	1392
Ala Glu Asp Tyr Leu Ser Val Val Leu Asn Gln Leu Cys Val Leu His	
450 455 460	
gag aaa acg cca gta agt gac aga gtc aca aaa tgc tgc aca gag tcc	1440
Glu Lys Thr Pro Val Ser Asp Arg Val Thr Lys Cys Cys Thr Glu Ser	
465 470 475 480	
ttg gtg aac agg cga cca tgc ttt tca gct ctg gaa gtc gat gaa aca	1488
Leu Val Asn Arg Arg Pro Cys Phe Ser Ala Leu Glu Val Asp Glu Thr	
485 490 495	
tac gtt ccc aaa gag ttt aat gct gaa aca ttc acc ttc cat gca gat	1536
Tyr Val Pro Lys Glu Phe Asn Ala Glu Thr Phe Thr Phe His Ala Asp	
500 505 510	
ata tgc aca ctt tct gag aag gag aga caa atc aag aaa caa act gca	1584
Ile Cys Thr Leu Ser Glu Lys Glu Arg Gln Ile Lys Lys Gln Thr Ala	
515 520 525	
ctt gtt gag ctt gtg aaa cac aag ccc aag gca aca aaa gag caa ctg	1632
Leu Val Glu Leu Val Lys His Lys Pro Lys Ala Thr Lys Glu Gln Leu	
530 535 540	
aaa gct gtt atg gat gat ttc gca gct ttt gta gag aag tgc tgc aag	1680
Lys Ala Val Met Asp Asp Phe Ala Ala Phe Val Glu Lys Cys Cys Lys	
545 550 555 560	
gct gac gat aag gag acc tgc ttt gcc gag gag ggt aaa aaa ctt gtt	1728
Ala Asp Asp Lys Glu Thr Cys Phe Ala Glu Glu Gly Lys Lys Leu Val	
565 570 575	

MAILING ADDRESS OF SENDER

U.S. Patent No. 6,994,857

Finnegan, Henderson, Farabow,
Garrett & Dunner, L.L.P.
901 New York Avenue, N.W.
Washington, D.C. 20001-4413

APR 18 2000

gct gca agt caa gct gcc tta ggc tta taacatctac atttaaaagc atctcag 1782
 Ala Ala Ser Gln Ala Ala Leu Gly Leu
 580 585

<210> 18
 <211> 585
 <212> PRT
 <213> Homo Sapiens

<400> 18
 Asp Ala His Lys Ser Glu Val Ala His Arg Phe Lys Asp Leu Gly Glu
 1 5 10 15

 Glu Asn Phe Lys Ala Leu Val Leu Ile Ala Phe Ala Gln Tyr Leu Gln
 20 25 30

 Gln Cys Pro Phe Glu Asp His Val Lys Leu Val Asn Glu Val Thr Glu
 35 40 45

 Phe Ala Lys Thr Cys Val Ala Asp Glu Ser Ala Glu Asn Cys Asp Lys
 50 55 60

 Ser Leu His Thr Leu Phe Gly Asp Lys Leu Cys Thr Val Ala Thr Leu
 65 70 75 80

 Arg Glu Thr Tyr Gly Glu Met Ala Asp Cys Cys Ala Lys Gln Glu Pro
 85 90 95

 Glu Arg Asn Glu Cys Phe Leu Gln His Lys Asp Asp Asn Pro Asn Leu
 100 105 110

 Pro Arg Leu Val Arg Pro Glu Val Asp Val Met Cys Thr Ala Phe His
 115 120 125

 Asp Asn Glu Glu Thr Phe Leu Lys Lys Tyr Leu Tyr Glu Ile Ala Arg
 130 135 140

 Arg His Pro Tyr Phe Tyr Ala Pro Glu Leu Leu Phe Phe Ala Lys Arg
 145 150 155 160

 Tyr Lys Ala Ala Phe Thr Glu Cys Cys Gln Ala Ala Asp Lys Ala Ala
 165 170 175

 Cys Leu Leu Pro Lys Leu Asp Glu Leu Arg Asp Glu Gly Lys Ala Ser
 180 185 190

 Ser Ala Lys Gln Arg Leu Lys Cys Ala Ser Leu Gln Lys Phe Gly Glu
 195 200 205

 Arg Ala Phe Lys Ala Trp Ala Val Ala Arg Leu Ser Gln Arg Phe Pro
 210 215 220

MAILING ADDRESS OF SENDER

U.S. Patent No. 6,994,857

Finnegan, Henderson, Farabow,
 Garrett & Dunner, L.L.P.
 901 New York Avenue, N.W.
 Washington, D.C. 20001-4413

Mar 13 2006

Lys	Ala	Glu	Phe	Ala	Glu	Val	Ser	Lys	Leu	Val	Thr	Asp	Leu	Thr	Lys	225	230	235	240
Val	His	Thr	Glu	Cys	Cys	His	Gly	Asp	Leu	Leu	Glu	Cys	Ala	Asp	Asp	245	250	255	
Arg	Ala	Asp	Leu	Ala	Lys	Tyr	Ile	Cys	Glu	Asn	Gln	Asp	Ser	Ile	Ser	260	265	270	
Ser	Lys	Leu	Lys	Glu	Cys	Cys	Glu	Lys	Pro	Leu	Leu	Glu	Lys	Ser	His	275	280	285	
Cys	Ile	Ala	Glu	Val	Glu	Asn	Asp	Glu	Met	Pro	Ala	Asp	Leu	Pro	Ser	290	295	300	
Leu	Ala	Ala	Asp	Phe	Val	Glu	Ser	Lys	Asp	Val	Cys	Lys	Asn	Tyr	Ala	305	310	315	320
Glu	Ala	Lys	Asp	Val	Phe	Leu	Gly	Met	Phe	Leu	Tyr	Glu	Tyr	Ala	Arg	325	330	335	
Arg	His	Pro	Asp	Tyr	Ser	Val	Val	Leu	Leu	Leu	Arg	Leu	Ala	Lys	Thr	340	345	350	
Tyr	Glu	Thr	Thr	Leu	Glu	Lys	Cys	Cys	Ala	Ala	Ala	Asp	Pro	His	Glu	355	360	365	
Cys	Tyr	Ala	Lys	Val	Phe	Asp	Glu	Phe	Lys	Pro	Leu	Val	Glu	Glu	Pro	370	375	380	
Gln	Asn	Leu	Ile	Lys	Gln	Asn	Cys	Glu	Leu	Phe	Glu	Gln	Leu	Gly	Glu	385	390	395	400
Tyr	Lys	Phe	Gln	Asn	Ala	Leu	Leu	Val	Arg	Tyr	Thr	Lys	Lys	Val	Pro	405	410	415	
Gln	Val	Ser	Thr	Pro	Thr	Leu	Val	Glu	Val	Ser	Arg	Asn	Leu	Gly	Lys	420	425	430	
Val	Gly	Ser	Lys	Cys	Cys	Lys	His	Pro	Glu	Ala	Lys	Arg	Met	Pro	Cys	435	440	445	
Ala	Glu	Asp	Tyr	Leu	Ser	Val	Val	Leu	Asn	Gln	Leu	Cys	Val	Leu	His	450	455	460	
Glu	Lys	Thr	Pro	Val	Ser	Asp	Arg	Val	Thr	Lys	Cys	Cys	Thr	Glu	Ser	465	470	475	480
Leu	Val	Asn	Arg	Arg	Pro	Cys	Phe	Ser	Ala	Leu	Glu	Val	Asp	Glu	Thr	485	490	495	

MAILING ADDRESS OF SENDER

U.S. Patent No. 6,994,857

Finnegan, Henderson, Farabow,
Garrett & Dunner, L.L.P.
901 New York Avenue, N.W.
Washington, D.C. 20001-4413

MAR 13 2006

Tyr Val Pro Lys Glu Phe Asn Ala Glu Thr Phe Thr Phe His Ala Asp
500 505 510

Ile Cys Thr Leu Ser Glu Lys Glu Arg Gln Ile Lys Lys Gln Thr Ala
515 520 525

Leu Val Glu Leu Val Lys His Lys Pro Lys Ala Thr Lys Glu Gln Leu
530 535 540

Lys Ala Val Met Asp Asp Phe Ala Ala Phe Val Glu Lys Cys Cys Lys
545 550 555 560

Ala Asp Asp Lys Glu Thr Cys Phe Ala Glu Glu Gly Lys Lys Leu Val
565 570 575

Ala Ala Ser Gln Ala Ala Leu Gly Leu
580 585

<210> 19

<211> 58

<212> DNA

<213> Artificial Sequence

<220>

<221> primer_bind

<223> primer used to generate XhoI and ClaI
site in pPPC0006

<400> 19

gcctcgagaa aagagatgca cacaagagtg aggttgctca tcgatttaaa gatttggg 58

<210> 20

<211> 59

<212> DNA

<213> Artificial Sequence

<220>

<221> primer_bind

<223> primer used in generation XhoI and ClaI
site in pPPC0006

<400> 20

aatcgatgag caacctcact cttgtgtgca tctcttttct cgaggctcct ggaataagc 59

<210> 21

<211> 24

<212> DNA

<213> Artificial Sequence

<220>

<221> primer_bind

<223> primer used in generation XhoI and ClaI

MAILING ADDRESS OF SENDER

U.S. Patent No. 6,994,857

Finnegan, Henderson, Farabow,
Garrett & Dunner, L.L.P.
901 New York Avenue, N.W.
Washington, D.C. 20001-4413

MAR 13 2006

site in pPPC0006

<400> 21

tacaaactta agagtccaat tagc

24

<210> 22

<211> 29

<212> DNA

<213> Artificial Sequence

<220>

<221> primer_bind

<223> primer used in generation XhoI and ClaI
site in pPPC0006

<400> 22

cacttctcta gagtggtttc atatgtctt

29

<210> 23

<211> 60

<212> DNA

<213> Artificial Sequence

<220>

<221> Misc_Structure

<223> Synthetic oligonucleotide used to alter restriction
sites in pPPC0007

<400> 23

aagctgcctt aggcttataa taaggcgcgc cggccggccg tttaaactaa gcttaattct 60

<210> 24

<211> 60

<212> DNA

<213> Artificial Sequence

<220>

<221> Misc_Structure

<223> Synthetic oligonucleotide used to alter restriction
sites in pPPC0007

<400> 24

agaattaagc ttagtttaaa cggccggccg gcgcgcctta ttataagcct aaggcagctt 60

<210> 25

<211> 32

<212> DNA

<213> Artificial Sequence

<220>

<221> primer_bind

<223> forward primer useful for generation of albumin

MAILING ADDRESS OF SENDER

U.S. Patent No. 6,994,857

Finnegan, Henderson, Farabow,
Garrett & Dunner, L.L.P.
901 New York Avenue, N.W.
Washington, D.C. 20001-4413

MAR 13 2006

fusion protein in which the albumin moiety is N-terminal
of the Therapeutic Protein

<220>

<221> misc_feature

<222> (18)

<223> n equals a,t,g, or c

<220>

<221> misc_feature

<222> (19)

<223> n equals a,t,g, or c

<220>

<221> misc_feature

<222> (20)

<223> n equals a,t,g, or c

<220>

<221> misc_feature

<222> (21)

<223> n equals a,t,g, or c

<220>

<221> misc_feature

<222> (22)

<223> n equals a,t,g, or c

<220>

<221> misc_feature

<222> (23)

<223> n equals a,t,g, or c

<220>

<221> misc_feature

<222> (24)

<223> n equals a,t,g, or c

<220>

<221> misc_feature

<222> (25)

<223> n equals a,t,g, or c

<220>

<221> misc_feature

<222> (26)

<223> n equals a,t,g, or c

<220>

<221> misc_feature

<222> (27)

MAILING ADDRESS OF SENDER

U.S. Patent No. 6,994,857

Finnegan, Henderson, Farabow,
Garrett & Dunner, L.L.P.
901 New York Avenue, N.W.
Washington, D.C. 20001-4413

FEB 13 2006

<223> n equals a,t,g, or c

<220>

<221> misc_feature

<222> (28)

<223> n equals a,t,g, or c

<220>

<221> misc_feature

<222> (29)

<223> n equals a,t,g, or c

<220>

<221> misc_feature

<222> (30)

<223> n equals a,t,g, or c

<220>

<221> misc_feature

<222> (31)

<223> n equals a,t,g, or c

<220>

<221> misc_feature

<222> (32)

<223> n equals a,t,g, or c

<400> 25

aagctgcctt aggcttannn nnnnnnnnnn nn

32

<210> 26

<211> 51

<212> DNA

<213> Artificial Sequence

<220>

<221> primer_bind

<223> reverse primer useful for generation of albumin fusion protein in which the albumin moiety is N-terminal of the Therapeutic Protein

<220>

<221> misc_feature

<222> (37)

<223> n equals a,t,g, or c

<220>

<221> misc_feature

<222> (38)

<223> n equals a,t,g, or c

<220>

<221> misc_feature

<222> (39)

MAILING ADDRESS OF SENDER

U.S. Patent No. 6,994,857

Finnegan, Henderson, Farabow,
Garrett & Dunner, L.L.P.
901 New York Avenue, N.W.
Washington, D.C. 20001-4413

<223> n equals a,t,g, or c

<220>

<221> misc_feature

<222> (40)

<223> n equals a,t,g, or c

<220>

<221> misc_feature

<222> (41)

<223> n equals a,t,g, or c

<220>

<221> misc_feature

<222> (42)

<223> n equals a,t,g, or c

<220>

<221> misc_feature

<222> (43)

<223> n equals a,t,g, or c

<220>

<221> misc_feature

<222> (44)

<223> n equals a,t,g, or c

<220>

<221> misc_feature

<222> (45)

<223> n equals a,t,g, or c

<220>

<221> misc_feature

<222> (46)

<223> n equals a,t,g, or c

<220>

<221> misc_feature

<222> (47)

<223> n equals a,t,g, or c

<220>

<221> misc_feature

<222> (48)

<223> n equals a,t,g, or c

<220>

<221> misc_feature

<222> (49)

<223> n equals a,t,g, or c

MAILING ADDRESS OF SENDER

U.S. Patent No. 6,994,857

Finnegan, Henderson, Farabow,
Garrett & Dunner, L.L.P.
901 New York Avenue, N.W.
Washington, D.C. 20001-4413

<220>
 <221> misc_feature
 <222> (50)
 <223> n equals a,t,g, or c

 <220>
 <221> misc_feature
 <222> (51)
 <223> n equals a,t,g, or c

 <400> 26
 gcgcgcggttt aaacggccgg cgcgcgcgcc ttattannnn nnnnnnnnnn n 51

 <210> 27
 <211> 33
 <212> DNA
 <213> Artificial Sequence
 <220>
 <223> forward primer useful for generation of albumin fusion
 protein in which the albumin moiety is c-terminal of the
 Therapeutic Protein

 <220>
 <221> misc_feature
 <222> (19)
 <223> n equals a,t,g, or c

 <220>
 <221> misc_feature
 <222> (20)
 <223> n equals a,t,g, or c

 <220>
 <221> misc_feature
 <222> (21)
 <223> n equals a,t,g, or c

 <220>
 <221> misc_feature
 <222> (22)
 <223> n equals a,t,g, or c

 <220>
 <221> misc_feature
 <222> (23)
 <223> n equals a,t,g, or c

 <220>
 <221> misc_feature
 <222> (24)
 <223> n equals a,t,g, or c

MAILING ADDRESS OF SENDER

U.S. Patent No. 6,994,857

Finnegan, Henderson, Farabow,
 Garrett & Dunner, L.L.P.
 901 New York Avenue, N.W.
 Washington, D.C. 20001-4413

MAR 13 2006

```

<220>
<221> misc_feature
<222> (25)
<223> n equals a,t,g, or c

<220>
<221> misc_feature
<222> (26)
<223> n equals a,t,g, or c

<220>
<221> misc_feature
<222> (27)
<223> n equals a,t,g, or c

<220>
<221> misc_feature
<222> (28)
<223> n equals a,t,g, or c

<220>
<221> misc_feature
<222> (29)
<223> n equals a,t,g, or c

<220>
<221> misc_feature
<222> (30)
<223> n equals a,t,g, or c

<220>
<221> misc_feature
<222> (31)
<223> n equals a,t,g, or c

<220>
<221> misc_feature
<222> (32)
<223> n equals a,t,g, or c

<220>
<221> misc_feature
<222> (33)
<223> n equals a,t,g, or c

<400> 27
aggagcgtcg acaaaagann nnnnnnnnnnn nnn

<210> 28
<211> 52
<212> DNA

```

33

MAILING ADDRESS OF SENDER

U.S. Patent No. 6,994,857

Finnegan, Henderson, Farabow,
Garrett & Dunner, L.L.P.
901 New York Avenue, N.W.
Washington, D.C. 20001-4413

MAR 13 2006

<213> Artificial Sequence
<220>
<221> primer_bind
<223> reverse primer useful for generation of albumin
fusion protein in which the albumin moiety is c-terminal of
the Therapeutic Protein

<220>
<221> misc_feature
<222> (38)
<223> n equals a,t,g, or c

<220>
<221> misc_feature
<222> (39)
<223> n equals a,t,g, or c

<220>
<221> misc_feature
<222> (40)
<223> n equals a,t,g, or c

<220>
<221> misc_feature
<222> (41)
<223> n equals a,t,g, or c

<220>
<221> misc_feature
<222> (42)
<223> n equals a,t,g, or c

<220>
<221> misc_feature
<222> (43)
<223> n equals a,t,g, or c

<220>
<221> misc_feature
<222> (44)
<223> n equals a,t,g, or c

<220>
<221> misc_feature
<222> (45)
<223> n equals a,t,g, or c

<220>
<221> misc_feature
<222> (46)
<223> n equals a,t,g, or c

MAILING ADDRESS OF SENDER

U.S. Patent No. 6,994,857

Finnegan, Henderson, Farabow,
Garrett & Dunner, L.L.P.
901 New York Avenue, N.W.
Washington, D.C. 20001-4413

MAR 13 2006

<220>
<221> misc_feature
<222> (47)
<223> n equals a,t,g, or c

<220>
<221> misc_feature
<222> (48)
<223> n equals a,t,g, or c

<220>
<221> misc_feature
<222> (49)
<223> n equals a,t,g, or c

<220>
<221> misc_feature
<222> (50)
<223> n equals a,t,g, or c

<220>
<221> misc_feature
<222> (51)
<223> n equals a,t,g, or c

<220>
<221> misc_feature
<222> (52)
<223> n equals a,t,g, or c

<400> 28
ctttaaatcg atgagcaacc tcactcttgt gtgcatcnnn nnnnnnnnnn nn 52

<210> 29
<211> 24
<212> PRT
<213> Artificial Sequence
<220>
<221> signal
<223> signal peptide of natural human serum albumin protein

<400> 29
Met Lys Trp Val Ser Phe Ile Ser Leu Leu Phe Leu Phe Ser Ser Ala
1 5 10 15
Tyr Ser Arg Ser Leu Asp Lys Arg
20

<210> 30
<211> 114
<212> DNA

MAILING ADDRESS OF SENDER

U.S. Patent No. 6,994,857

Finnegan, Henderson, Farabow,
Garrett & Dunner, L.L.P.
901 New York Avenue, N.W.
Washington, D.C. 20001-4413

```

<213> Artificial Sequence

<220>
<221> primer_bind
<223> forward primer useful for generation of PC4:HSA
albumin fusion VECTOR

<220>
<221> misc_feature
<222> (5)..(10)
<223> BamHI restriction site

<220>
<221> misc_feature
<222> (11)..(16)
<223> Hind III restriction site

<220>
<221> misc_feature
<222> (17)..(27)
<223> Kozak sequence

<220>
<221> misc_feature
<222> (25)..(97)
<223> cds natural signal sequence of human serum albumin

<220>
<221> misc_feature
<222> (75)..(81)
<223> XhoI restriction site

<220>
<221> misc_feature
<222> (98)..(114)
<223> cds first six amino acids of human serum albumin

<400> 30
tcagggatcc aagcttcgc caccatgaag tgggtaacct ttatttcct tctttttctc 60

tttagctcgg cttactcgag ggggtgtgtt cgctgagatg cacacaagag tgag      114

<210> 31
<211> 43
<212> DNA
<213> Artificial Sequence

<220>
<221> primer_bind
<223> reverse primer useful for generation of
PC4:HSA albumin fusion VECTOR

```

MAILING ADDRESS OF SENDER

U.S. Patent No. 6,994,857

Finnegan, Henderson, Farabow,
Garrett & Dunner, L.L.P.
901 New York Avenue, N.W.
Washington, D.C. 20001-4413

2006


```

<220>
<221> misc_feature
<222> (6)..(11)
<223> Asp718 restriction site

<220>
<221> misc_feature
<222> (12)..(17)
<223> EcoRI restriction site

<220>
<221> misc_feature
<222> (15)..(17)
<223> reverse complement of stop codon

<220>
<221> misc_feature
<222> (18)..(25)
<223> AscI restriction site

<220>
<221> misc_feature
<222> (18)..(43)
<223> reverse complement of DNA sequence encoding last 9 amino acids

<400> 31
gcagcgggtac cgaattcggc ggcgccttata agcctaaggc agc
43

<210> 32
<211> 46
<212> DNA
<213> Artificial Sequence
<220>
<221> primer_bind
<223> forward primer useful for inserting Therapeutic
protein into pC4:HSA vector

<220>
<221> misc_feature
<222> (29)
<223> n equals a,t,g, or c

<220>
<221> misc_feature
<222> (30)
<223> n equals a,t,g, or c

<220>
<221> misc_feature
<222> (31)
<223> n equals a,t,g, or c

```

MAILING ADDRESS OF SENDER

U.S. Patent No. 6,994,857

Finnegan, Henderson, Farabow,
Garrett & Dunner, L.L.P.
901 New York Avenue, N.W.
Washington, D.C. 20001-4413

<220>
<221> misc_feature
<222> (32)
<223> n equals a,t,g, or c

<220>
<221> misc_feature
<222> (33)
<223> n equals a,t,g, or c

<220>
<221> misc_feature
<222> (34)
<223> n equals a,t,g, or c

<220>
<221> misc_feature
<222> (35)
<223> n equals a,t,g, or c

<220>
<221> misc_feature
<222> (36)
<223> n equals a,t,g, or c

<220>
<221> misc_feature
<222> (37)
<223> n equals a,t,g, or c

<220>
<221> misc_feature
<222> (38)
<223> n equals a,t,g, or c

<220>
<221> misc_feature
<222> (39)
<223> n equals a,t,g, or c

<220>
<221> misc_feature
<222> (40)
<223> n equals a,t,g, or c

<220>
<221> misc_feature
<222> (41)
<223> n equals a,t,g, or c

<220>
<221> misc_feature

MAILING ADDRESS OF SENDER

U.S. Patent No. 6,994,857

Finnegan, Henderson, Farabow,
Garrett & Dunner, L.L.P.
901 New York Avenue, N.W.
Washington, D.C. 20001-4413

MAR 13 2006

<222> (42)
 <223> n equals a,t,g, or c

 <220>
 <221> misc_feature
 <222> (43)
 <223> n equals a,t,g, or c

 <220>
 <221> misc_feature
 <222> (44)
 <223> n equals a,t,g, or c

 <220>
 <221> misc_feature
 <222> (45)
 <223> n equals a,t,g, or c

 <220>
 <221> misc_feature
 <222> (46)
 <223> n equals a,t,g, or c

 <400> 32
 ccgccgctcg aggggtgtgt ttcgtcgann nnnnnnnnnn nnnnnn

 <210> 33
 <211> 55
 <212> DNA
 <213> Artificial Sequence
 <220>
 <221> primer_bind
 <223> reverse primer useful for inserting Therapeutic
 protein into pC4:HSA vector

 <220>
 <221> misc_feature
 <222> (38)
 <223> n equals a,t,g, or c

 <220>
 <221> misc_feature
 <222> (39)
 <223> n equals a,t,g, or c

 <220>
 <221> misc_feature
 <222> (40)
 <223> n equals a,t,g, or c

 <220>
 <221> misc_feature

46

MAILING ADDRESS OF SENDER

U.S. Patent No. 6,994,857

Finnegan, Henderson, Farabow,
 Garrett & Dunner, L.L.P.
 901 New York Avenue, N.W.
 Washington, D.C. 20001-4413

MAR 19 2006

<222> (41)
<223> n equals a,t,g, or c

<220>
<221> misc_feature
<222> (42)
<223> n equals a,t,g, or c

<220>
<221> misc_feature
<222> (43)
<223> n equals a,t,g, or c

<220>
<221> misc_feature
<222> (44)
<223> n equals a,t,g, or c

<220>
<221> misc_feature
<222> (45)
<223> n equals a,t,g, or c

<220>
<221> misc_feature
<222> (46)
<223> n equals a,t,g, or c

<220>
<221> misc_feature
<222> (47)
<223> n equals a,t,g, or c

<220>
<221> misc_feature
<222> (48)
<223> n equals a,t,g, or c

<220>
<221> misc_feature
<222> (49)
<223> n equals a,t,g, or c

<220>
<221> misc_feature
<222> (50)
<223> n equals a,t,g, or c

<220>
<221> misc_feature
<222> (51)

MAILING ADDRESS OF SENDER

U.S. Patent No. 6,994,857

Finnegan, Henderson, Farabow,
Garrett & Dunner, L.L.P.
901 New York Avenue, N.W.
Washington, D.C. 20001-4413

MAR 13 2006

<223> n equals a,t,g, or c

<220>

<221> misc_feature

<222> (52)

<223> n equals a,t,g, or c

<220>

<221> misc_feature

<222> (53)

<223> n equals a,t,g, or c

<220>

<221> misc_feature

<222> (54)

<223> n equals a,t,g, or c

<220>

<221> misc_feature

<222> (55)

<223> n equals a,t,g, or c

<400> 33

agtcccatcg atgagcaacc tcactcttgt gtgcacnnnn nnnnnnnnnnn nnnnn 55

<210> 34

<211> 17

<212> PRT

<213> Artificial Sequence

<220>

<221> signal

<223> Stanniocalcin signal peptide

<400> 34

Met	Leu	Gln	Asn	Ser	Ala	Val	Leu	Leu	Leu	Leu	Val	Ile	Ser	Ala	Ser
1				5					10					15	

Ala

<210> 35

<211> 22

<212> PRT

<213> Artificial Sequence

<220>

<221> signal

<223> Synthetic signal peptide

<400> 35

Met	Pro	Thr	Trp	Ala	Trp	Trp	Leu	Phe	Leu	Val	Leu	Leu	Leu	Ala	Leu
1				5					10					15	

MAILING ADDRESS OF SENDER

U.S. Patent No. 6,994,857

Finnegan, Henderson, Farabow,
Garrett & Dunner, L.L.P.
901 New York Avenue, N.W.
Washington, D.C. 20001-4413

Trp Ala Pro Ala Arg Gly
20

<210> 36

<211> 23

<212> DNA

<213> Artificial Sequence

<220>

<221>primer_bind

<223>Degenerate VH forward primer useful for
amplifying human VH domains

<400> 36

caggtgcagc tgggtgcagtc tgg

23

<210> 37

<211> 23

<212> DNA

<213> Artificial Sequence

<220>

<221>primer_bind

<223>Degenerate VH forward primer useful for
amplifying human VH domains

<400> 37

caggtcaact taagggagtc tgg

23

<210> 38

<211> 23

<212> DNA

<213> Artificial Sequence

<220>

<221>primer_bind

<223>Degenerate VH forward primer useful for
amplifying human VH domains

<400> 38

gaggtgcagc tgggtggagtc tgg

23

<210> 39

<211> 23

<212> DNA

<213> Artificial Sequence

<220>

<221>primer_bind

<223>Degenerate VH forward primer useful for
amplifying human VH domains

<400> 39

MAILING ADDRESS OF SENDER

U.S. Patent No. 6,994,857

Finnegan, Henderson, Farabow,
Garrett & Dunner, L.L.P.
901 New York Avenue, N.W.
Washington, D.C. 20001-4413

caggtgcagc tgcaggagtc ggg	23
<210> 40	
<211> 23	
<212> DNA	
<213> Artificial Sequence	
<220>	
<221>primer_bind	
<223>Degenerate VH forward primer useful for amplifying human VH domains	
<400> 40	
gaggtgcagc tgttcagtc tgc	23
<210> 41	
<211> 23	
<212> DNA	
<213> Artificial Sequence	
<220>	
<221>primer_bind	
<223>Degenerate VH forward primer useful for amplifying human VH domains	
<400> 41	
caggtacagc tgcagcagtc agg	23
<210> 42	
<211> 24	
<212> DNA	
<213> Artificial Sequence	
<220>	
<221>primer_bind	
<223>Degenerate JH reverse primer useful for amplifying human VH domains	
<400> 42	
tgaggagacg gtgaccaggg tgcc	24
<210> 43	
<211> 24	
<212> DNA	
<213> Artificial Sequence	
<220>	
<221>primer_bind	
<223>Degenerate JH reverse primer useful for amplifying human VH domains	
<400> 43	
tgaagagacg gtgaccattg tccc	24
<210> 44	

MAILING ADDRESS OF SENDER

U.S. Patent No. 6,994,857

Finnegan, Henderson, Farabow,
Garrett & Dunner, L.L.P.
901 New York Avenue, N.W.
Washington, D.C. 20001-4413

MAR 13 2006

<211> 24	
<212> DNA	
<213> Artificial Sequence	
<220>	
<221>primer_bind	
<223>Degenerate JH reverse primer useful for amplifying human VH domains	
<400> 44	
tgaggagacg gtgaccaggg ttcc	24
<210> 45	
<211> 24	
<212> DNA	
<213> Artificial Sequence	
<220>	
<221>primer_bind	
<223>Degenerate JH reverse primer useful for amplifying human VH domains	
<400> 45	
tgaggagacg gtgaccgtgg tccc	24
<210> 46	
<211> 23	
<212> DNA	
<213> Artificial Sequence	
<220>	
<221>primer_bind	
<223>Degenerate Vkappa forward primer useful for amplifying human VL domains	
<400> 46	
gacatccaga tgaccagtc tcc	23
<210> 47	
<211> 23	
<212> DNA	
<213> Artificial Sequence	
<220>	
<221>primer_bind	
<223>Degenerate Vkappa forward primer useful for amplifying human VL domains	
<400> 47	
gatgttgtga tgactcagtc tcc	23
<210> 48	
<211> 23	
<212> DNA	
<213> Artificial Sequence	
<220>	

MAILING ADDRESS OF SENDER

U.S. Patent No. 6,994,857

Finnegan, Henderson, Farabow,
Garrett & Dunner, L.L.P.
901 New York Avenue, N.W.
Washington, D.C. 20001-4413

MAR 13 2006

<221>primer_bind <223>Degenerate Vkappa forward primer useful for amplifying human VL domains	
<400> 48 gatattgtga tgactcagtc tcc	23
<210> 49 <211> 23 <212> DNA <213> Artificial Sequence <220> <221>primer_bind <223>Degenerate Vkappa forward primer useful for amplifying human VL domains	
<400> 49 gaaattgtgt tgacgcagtc tcc	23
<210> 50 <211> 23 <212> DNA <213> Artificial Sequence <220> <221>primer_bind <223>Degenerate Vkappa forward primer useful for amplifying human VL domains	
<400> 50 gacatcgtga tgacccagtc tcc	23
<210> 51 <211> 23 <212> DNA <213> Artificial Sequence <220> <221>primer_bind <223>Degenerate Vkappa forward primer useful for amplifying human VL domains	
<400> 51 gaaacgacac tcacgcagtc tcc	23
<210> 52 <211> 23 <212> DNA <213> Artificial Sequence <220> <221>primer_bind <223>Degenerate Vkappa forward primer useful for amplifying human VL domains	

MAILING ADDRESS OF SENDER

U.S. Patent No. 6,994,857

Finnegan, Henderson, Farabow,
Garrett & Dunner, L.L.P.
901 New York Avenue, N.W.
Washington, D.C. 20001-4413

MAR 13 2006

<400> 52	
gaaattgtgc tgactcagtc tcc	23
<210> 53	
<211> 23	
<212> DNA	
<213> Artificial Sequence	
<220>	
<221>primer_bind	
<223>Degenerate Vlambda forward primer useful for amplifying human VL domains	
<400> 53	
cagtctgtgt tgacgcagcc gcc	23
<210> 54	
<211> 23	
<212> DNA	
<213> Artificial Sequence	
<220>	
<221>primer_bind	
<223>Degenerate Vlambda forward primer useful for amplifying human VL domains	
<400> 54	
cagtctgccc tgactcagcc tgc	23
<210> 55	
<211> 23	
<212> DNA	
<213> Artificial Sequence	
<220>	
<221>primer_bind	
<223>Degenerate Vlambda forward primer useful for amplifying human VL domains	
<400> 55	
tcctatgtgc tgactcagcc acc	23
<210> 56	
<211> 23	
<212> DNA	
<213> Artificial Sequence	
<220>	
<221>primer_bind	
<223>Degenerate Vlambda forward primer useful for amplifying human VL domains	
<400> 56	
tcttctgagc tgactcagga ccc	23
<210> 57	

MAILING ADDRESS OF SENDER

U.S. Patent No. 6,994,857

Finnegan, Henderson, Farabow,
Garrett & Dunner, L.L.P.
901 New York Avenue, N.W.
Washington, D.C. 20001-4413

MAY 13 2000

<211> 23	
<212> DNA	
<213> Artificial Sequence	
<220>	
<221>primer_bind	
<223>Degenerate Vlambda forward primer useful for amplifying human VL domains	
 <400> 57	
cacgttatac tgactcaacc gcc	23
 <210> 58	
<211> 23	
<212> DNA	
<213> Artificial Sequence	
<220>	
<221>primer_bind	
<223>Degenerate Vlambda forward primer useful for amplifying human VL domains	
 <400> 58	
caggctgtgc tcactcagcc gtc	23
 <210> 59	
<211> 23	
<212> DNA	
<213> Artificial Sequence	
<220>	
<221>primer_bind	
<223>Degenerate Vlambda forward primer useful for amplifying human VL domains	
 <400> 59	
aattttatgc tgactcagcc cca	23
 <210> 60	
<211> 24	
<212> DNA	
<213> Artificial Sequence	
<220>	
<221>primer_bind	
<223>Degenerate Jkappa reverse primer useful for amplifying human VL domains	
 <400> 60	
acgtttgatt tccaccttgg tccc	24
 <210> 61	
<211> 24	
<212> DNA	
<213> Artificial Sequence	
<220>	

MAILING ADDRESS OF SENDER

U.S. Patent No. 6,994,857

Finnegan, Henderson, Farabow,
Garrett & Dunner, L.L.P.
901 New York Avenue, N.W.
Washington, D.C. 20001-4413

<221>primer_bind <223>Degenerate Jkappa reverse primer useful for amplifying human VL domains <400> 61 acgtttgatc tccagcttgg tccc	24
<210> 62 <211> 24 <212> DNA <213> Artificial Sequence <220> <221>primer_bind <223>Degenerate Jkappa reverse primer useful for amplifying human VL domains <400> 62 acgtttgata tccactttgg tccc	
24	
<210> 63 <211> 24 <212> DNA <213> Artificial Sequence <220> <221>primer_bind <223>Degenerate Jkappa reverse primer useful for amplifying human VL domains <400> 63 acgtttgatc tccaccttgg tccc	
24	
<210> 64 <211> 24 <212> DNA <213> Artificial Sequence <220> <221>primer_bind <223>Degenerate Jkappa reverse primer useful for amplifying human VL domains <400> 64 acgtttaatc tccagtcgtg tccc	
24	
<210> 65 <211> 23 <212> DNA <213> Artificial Sequence <220> <221>primer_bind <223>Degenerate Jlambda reverse primer useful for amplifying human VL domains	

MAILING ADDRESS OF SENDER

U.S. Patent No. 6,994,857

Finnegan, Henderson, Farabow,
Garrett & Dunner, L.L.P.
901 New York Avenue, N.W.
Washington, D.C. 20001-4413

MAR 13 2006

<400> 65 cagtctgtgt tgacgcagcc gcc	23
<210> 66	
<211> 23	
<212> DNA	
<213> Artificial Sequence	
<220>	
<221>primer_bind	
<223>Degenerate Jlambda reverse primer useful for amplifying human VL domains	
<400> 66 cagtctgccc tgactcagcc tgc	23
<210> 67	
<211> 23	
<212> DNA	
<213> Artificial Sequence	
<220>	
<221>primer_bind	
<223>Degenerate Jlambda reverse primer useful for amplifying human VL domains	
<400> 67 tcctatgtgc tgactcagcc acc	23
<210> 68	
<211> 23	
<212> DNA	
<213> Artificial Sequence	
<220>	
<221>primer_bind	
<223>Degenerate Jlambda reverse primer useful for amplifying human VL domains	
<400> 68 tcttctgagc tgactcagga ccc	23
<210> 69	
<211> 23	
<212> DNA	
<213> Artificial Sequence	
<220>	
<221>primer_bind	
<223>Degenerate Jlambda reverse primer useful for amplifying human VL domains	
<400> 69 cacgttatac tgactcaacc gcc	23
<210> 70	

MAILING ADDRESS OF SENDER

U.S. Patent No. 6,994,857

Finnegan, Henderson, Farabow,
Garrett & Dunner, L.L.P.
901 New York Avenue, N.W.
Washington, D.C. 20001-4413

MAR 13 2006

<211> 23
 <212> DNA
 <213> Artificial Sequence
 <220>
 <221>primer_bind
 <223>Degenerate Jlambda reverse primer useful for
 amplifying human VL domains

<400> 70
 caggctgtgc tcaactcagcc gtc 23

<210> 71
 <211> 23
 <212> DNA
 <213> Artificial Sequence
 <220>
 <221>primer_bind
 <223>Degenerate Jlambda reverse primer useful for
 amplifying human VL domains

<400> 71
 aattttatgc tgactcagcc cca 23

<210> 72
 <211> 15
 <212> PRT
 <213> Artificial Sequence
 <220>
 <221>turn
 <223>Linker peptide that may be used to join VH
 and VL domains in an scFv.

<400> 72
 Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser
 1 5 10 15

<210> 73
 <211> 23
 <212> PRT
 <213> Homo sapiens

<400> 73
 Cys Cys Cys Ala Ala Gly Ala Ala Thr Thr Cys Cys Cys Thr Thr Ala
 1 5 10 15
 Thr Cys Cys Ala Gly Gly Cys
 20

<210> 74
 <211> 429
 <212> PRT

MAILING ADDRESS OF SENDER

U.S. Patent No. 6,994,857

Finnegan, Henderson, Farabow,
 Garrett & Dunner, L.L.P.
 901 New York Avenue, N.W.
 Washington, D.C. 20001-4413

MAR 13 2006

<213> Homo sapiens

<400> 74

```
Met Cys Pro Gly Ala Leu Trp Val Ala Leu Pro Leu Leu Ser Leu Leu
  1              5              10              15

Ala Gly Ser Leu Gln Gly Lys Pro Leu Gln Ser Trp Gly Arg Gly Ser
      20              25              30

Ala Gly Gly Asn Ala His Ser Pro Leu Gly Val Pro Gly Gly Gly Leu
      35              40              45

Pro Glu His Thr Phe Asn Leu Lys Met Phe Leu Glu Asn Val Lys Val
      50              55              60

Asp Phe Leu Arg Ser Leu Asn Leu Ser Gly Val Pro Ser Gln Asp Lys
      65              70              75              80

Thr Arg Val Glu Pro Pro Gln Tyr Met Ile Asp Leu Tyr Asn Arg Tyr
      85              90              95

Thr Ser Asp Lys Ser Thr Thr Pro Ala Ser Asn Ile Val Arg Ser Phe
      100             105             110

Ser Met Glu Asp Ala Ile Ser Ile Thr Ala Thr Glu Asp Phe Pro Phe
      115             120             125

Gln Lys His Ile Leu Leu Phe Asn Ile Ser Ile Pro Arg His Glu Gln
      130             135             140

Ile Thr Arg Ala Glu Leu Arg Leu Tyr Val Ser Cys Gln Asn His Val
      145             150             155             160

Asp Pro Ser His Asp Leu Lys Gly Ser Val Val Ile Tyr Asp Val Leu
      165             170             175

Asp Gly Thr Asp Ala Trp Asp Ser Ala Thr Glu Thr Lys Thr Phe Leu
      180             185             190

Val Ser Gln Asp Ile Gln Asp Glu Gly Trp Glu Thr Leu Glu Val Ser
      195             200             205

Ser Ala Val Lys Arg Trp Val Arg Ser Asp Ser Thr Lys Ser Lys Asn
      210             215             220

Lys Leu Glu Val Thr Val Glu Ser His Arg Lys Gly Cys Asp Thr Leu
      225             230             235             240

Asp Ile Ser Val Pro Pro Gly Ser Arg Asn Leu Pro Phe Phe Val Val
      245             250             255
```

MAILING ADDRESS OF SENDER

U.S. Patent No. 6,994,857

Finnegan, Henderson, Farabow,
Garrett & Dunner, L.L.P.
901 New York Avenue, N.W.
Washington, D.C. 20001-4413

MAR 13 2002

Phe Ser Asn Asp His Ser Ser Gly Thr Lys Glu Thr Arg Leu Glu Leu
 260 265 270
 Arg Glu Met Ile Ser His Glu Gln Glu Ser Val Leu Lys Lys Leu Ser
 275 280 285
 Lys Asp Gly Ser Thr Glu Ala Gly Glu Ser Ser His Glu Glu Asp Thr
 290 295 300
 Asp Gly His Val Ala Ala Gly Ser Thr Leu Ala Arg Arg Lys Arg Ser
 305 310 315 320
 Ala Gly Ala Gly Ser His Cys Gln Lys Thr Ser Leu Arg Val Asn Phe
 325 330 335
 Glu Asp Ile Gly Trp Asp Ser Trp Ile Ile Ala Pro Lys Glu Tyr Glu
 340 345 350
 Ala Tyr Glu Cys Lys Gly Gly Cys Phe Phe Pro Leu Ala Asp Asp Val
 355 360 365
 Thr Pro Thr Lys His Ala Ile Val Gln Thr Leu Val His Leu Lys Phe
 370 375 380
 Pro Thr Lys Val Gly Lys Ala Cys Cys Val Pro Thr Lys Leu Ser Pro
 385 390 395 400
 Ile Ser Val Leu Tyr Lys Asp Asp Met Gly Val Pro Thr Leu Lys Tyr
 405 410 415
 His Tyr Glu Gly Met Ser Val Ala Glu Cys Gly Cys Arg
 420 425
 <210> 75
 <211> 280
 <212> PRT
 <213> Homo sapiens
 <400> 75
 Met Ala Pro Ser Gly Ser Leu Ala Val Pro Leu Ala Val Leu Val Leu
 1 5 10 15
 Leu Leu Trp Gly Ala Pro Trp Thr His Gly Arg Arg Ser Asn Val Arg
 20 25 30
 Val Ile Thr Asp Glu Asn Trp Arg Glu Leu Leu Glu Gly Asp Trp Met
 35 40 45
 Ile Glu Phe Tyr Ala Pro Trp Cys Pro Ala Cys Gln Asn Leu Gln Pro
 50 55 60

MAILING ADDRESS OF SENDER

U.S. Patent No. 6,994,857

Finnegan, Henderson, Farabow,
 Garrett & Dunner, L.L.P.
 901 New York Avenue, N.W.
 Washington, D.C. 20001-4413

MAR 13 2006

Glu	Trp	Glu	Ser	Phe	Ala	Glu	Trp	Gly	Glu	Asp	Leu	Glu	Val	Asn	Ile	65	70	75	80
Ala	Lys	Val	Asp	Val	Thr	Glu	Gln	Pro	Gly	Leu	Ser	Gly	Arg	Phe	Ile	85	90	95	
Ile	Thr	Ala	Leu	Pro	Thr	Ile	Tyr	His	Cys	Lys	Asp	Gly	Glu	Phe	Arg	100	105	110	
Arg	Tyr	Gln	Gly	Pro	Arg	Thr	Lys	Lys	Asp	Phe	Ile	Asn	Phe	Ile	Ser	115	120	125	
Asp	Lys	Glu	Trp	Lys	Ser	Ile	Glu	Pro	Val	Ser	Ser	Trp	Phe	Gly	Pro	130	135	140	
Gly	Ser	Val	Leu	Met	Ser	Ser	Met	Ser	Ala	Leu	Phe	Gln	Leu	Ser	Met	145	150	155	160
Trp	Ile	Arg	Thr	Cys	His	Asn	Tyr	Phe	Ile	Glu	Asp	Leu	Gly	Leu	Pro	165	170	175	
Val	Trp	Gly	Ser	Tyr	Thr	Val	Phe	Ala	Leu	Ala	Thr	Leu	Phe	Ser	Gly	180	185	190	
Leu	Leu	Leu	Gly	Leu	Cys	Met	Ile	Phe	Val	Ala	Asp	Cys	Leu	Cys	Pro	195	200	205	
Ser	Lys	Arg	Arg	Arg	Pro	Gln	Pro	Tyr	Pro	Tyr	Pro	Ser	Lys	Lys	Leu	210	215	220	
Leu	Ser	Glu	Ser	Ala	Gln	Pro	Leu	Lys	Lys	Val	Glu	Glu	Glu	Gln	Glu	225	230	235	240
Ala	Asp	Glu	Glu	Asp	Val	Ser	Glu	Glu	Glu	Ala	Glu	Ser	Lys	Glu	Gly	245	250	255	
Thr	Asn	Lys	Asp	Phe	Pro	Gln	Asn	Ala	Ile	Arg	Gln	Arg	Ser	Leu	Gly	260	265	270	
Pro	Ser	Leu	Ala	Thr	Asp	Lys	Ser									275	280		

<210> 76
 <211> 112
 <212> PRT
 <213> Homo sapiens

<400> 76
 Met Phe Trp Val Met Glu Thr Ala Lys Pro Pro Val Ser Glu Asp Ser
 1 5 10 15

MAILING ADDRESS OF SENDER

U.S. Patent No. 6,994,857

Finnegan, Henderson, Farabow,
 Garrett & Dunner, L.L.P.
 901 New York Avenue, N.W.
 Washington, D.C. 20001-4413

MAR 13 2006

Phe Arg Leu Pro Arg Lys Trp Gly Trp Arg Thr Glu Ala Thr Ala Pro
20 25 30
His Ala Pro Val Pro Gln Ser Ile Cys Pro Arg Tyr Thr Ser Pro Cys
35 40 45
Ala Pro His Asp Cys Gly Ser Gln Thr Val Gln Gly Asn Ser Leu Ser
50 55 60
Leu Phe Tyr Thr Leu Ser His Lys Ala Pro Gln Leu Pro His Arg Val
65 70 75 80
Pro Ala Pro Leu Phe Cys Lys Tyr Val Lys Arg Lys Lys Cys Lys Arg
85 90 95
Trp Ser Leu Gly Trp Ser Ser Ser Leu Gln Leu Arg Leu Leu Thr Met
100 105 110
<210> 77
<211> 346
<212> PRT
<213> Homo sapiens
<400> 77
Met Asp Pro Ala Arg Lys Ala Gly Ala Gln Ala Met Ile Trp Thr Ala
1 5 10 15
Gly Trp Leu Leu Leu Leu Leu Leu Arg Gly Gly Ala Gln Ala Leu Glu
20 25 30
Cys Tyr Ser Cys Val Gln Lys Ala Asp Asp Gly Cys Ser Pro Asn Lys
35 40 45
Met Lys Thr Val Lys Cys Ala Pro Gly Val Asp Val Cys Thr Glu Ala
50 55 60
Val Gly Ala Val Glu Thr Ile His Gly Gln Phe Ser Leu Ala Val Arg
65 70 75 80
Gly Cys Gly Ser Gly Leu Pro Gly Lys Asn Asp Arg Gly Leu Asp Leu
85 90 95
His Gly Leu Leu Ala Phe Ile Gln Leu Gln Gln Cys Ala Gln Asp Arg
100 105 110
Cys Asn Ala Lys Leu Asn Leu Thr Ser Arg Ala Leu Asp Pro Ala Gly
115 120 125
Asn Glu Ser Ala Tyr Pro Pro Asn Gly Val Glu Cys Tyr Ser Cys Val
130 135 140

MAILING ADDRESS OF SENDER

U.S. Patent No. 6,994,857

Finnegan, Henderson, Farabow,
Garrett & Dunner, L.L.P.
901 New York Avenue, N.W.
Washington, D.C. 20001-4413

MAR 13 2006

Gly Leu Ser Arg Glu Ala Cys Gln Gly Thr Ser Pro Pro Val Val Ser
 145 150 155 160
 Cys Tyr Asn Ala Ser Asp His Val Tyr Lys Gly Cys Phe Asp Gly Asn
 165 170 175
 Val Thr Leu Thr Ala Ala Asn Val Thr Val Ser Leu Pro Val Arg Gly
 180 185 190
 Cys Val Gln Asp Glu Phe Cys Thr Arg Asp Gly Val Thr Gly Pro Gly
 195 200 205
 Phe Thr Leu Ser Gly Ser Cys Cys Gln Gly Ser Arg Cys Asn Ser Asp
 210 215 220
 Leu Arg Asn Lys Thr Tyr Phe Ser Pro Arg Ile Pro Pro Leu Val Arg
 225 230 235 240
 Leu Pro Pro Pro Glu Pro Thr Thr Val Ala Ser Thr Thr Ser Val Thr
 245 250 255
 Thr Ser Thr Ser Ala Pro Val Arg Pro Thr Ser Thr Thr Lys Pro Met
 260 265 270
 Pro Ala Pro Thr Ser Gln Thr Pro Arg Gln Gly Val Glu His Glu Ala
 275 280 285
 Ser Arg Asp Glu Glu Pro Arg Leu Thr Gly Gly Ala Ala Gly His Gln
 290 295 300
 Asp Arg Ser Asn Ser Gly Gln Tyr Pro Ala Lys Gly Gly Pro Gln Gln
 305 310 315 320
 Pro His Asn Lys Gly Cys Val Ala Pro Thr Ala Gly Leu Ala Ala Leu
 325 330 335
 Leu Leu Ala Val Ala Ala Gly Val Leu Leu
 340 345

<210> 78
 <211> 272
 <212> PRT
 <213> Homo sapiens

<400> 78
 Met Lys Gly Lys Lys Gly Ile Val Ala Ala Ser Gly Ser Glu Thr Glu
 1 5 10 15

Asp Glu Asp Ser Met Asp Ile Pro Leu Asp Leu Ser Ser Ser Ala Gly
 20 25 30

MAILING ADDRESS OF SENDER

U.S. Patent No. 6,994,857

Finnegan, Henderson, Farabow,
 Garrett & Dunner, L.L.P.
 901 New York Avenue, N.W.
 Washington, D.C. 20001-4413

Ser Gly Lys Arg Arg Arg Arg Gly Asn Leu Pro Lys Glu Ser Val Gln
 35 40 45
 Ile Leu Arg Asp Trp Leu Tyr Glu His Arg Tyr Asn Ala Tyr Pro Ser
 50 55 60
 Glu Gln Glu Lys Ala Leu Leu Ser Gln Gln Thr His Leu Ser Thr Leu
 65 70 75 80
 Gln Val Cys Asn Trp Phe Ile Asn Ala Arg Arg Arg Leu Leu Pro Asp
 85 90 95
 Met Leu Arg Lys Asp Gly Lys Asp Pro Asn Gln Phe Thr Ile Ser Arg
 100 105 110
 Arg Gly Ala Lys Ile Ser Glu Thr Ser Ser Val Glu Ser Val Met Gly
 115 120 125
 Ile Lys Asn Phe Met Pro Ala Leu Glu Glu Thr Pro Phe His Ser Cys
 130 135 140
 Thr Ala Gly Pro Asn Pro Thr Leu Gly Arg Pro Leu Ser Pro Lys Pro
 145 150 155 160
 Ser Ser Pro Gly Ser Val Leu Ala Arg Pro Ser Val Ile Cys His Thr
 165 170 175
 Thr Val Thr Ala Leu Lys Asp Val Pro Phe Ser Leu Cys Gln Ser Val
 180 185 190
 Gly Val Gly Gln Asn Thr Asp Ile Gln Gln Ile Ala Ala Lys Asn Phe
 195 200 205
 Thr Asp Thr Ser Leu Met Tyr Pro Glu Asp Thr Cys Lys Ser Gly Pro
 210 215 220
 Ser Thr Asn Thr Gln Ser Gly Leu Phe Asn Thr Pro Pro Pro Thr Pro
 225 230 235 240
 Pro Asp Leu Asn Gln Asp Phe Ser Gly Phe Gln Leu Leu Val Asp Val
 245 250 255
 Ala Leu Lys Arg Ala Ala Glu Met Glu Leu Gln Ala Lys Leu Thr Ala
 260 265 270

<210> 79
 <211> 167
 <212> PRT
 <213> Homo sapiens

MAILING ADDRESS OF SENDER

U.S. Patent No. 6,994,857

Finnegan, Henderson, Farabow,
 Garrett & Dunner, L.L.P.
 901 New York Avenue, N.W.
 Washington, D.C. 20001-4413

<400> 79
Met Leu Thr Val Ala Leu Leu Ala Leu Leu Cys Ala Ser Ala Ser Gly
1 5 10 15
Asn Ala Ile Gln Ala Arg Ser Ser Ser Tyr Ser Gly Glu Tyr Gly Gly
20 25 30
Gly Gly Gly Lys Arg Phe Ser His Ser Gly Asn Gln Leu Asp Gly Pro
35 40 45
Ile Thr Ala Leu Arg Val Arg Val Asn Thr Tyr Tyr Ile Val Gly Leu
50 55 60
Gln Val Arg Tyr Gly Lys Val Trp Ser Asp Tyr Val Gly Gly Arg Asn
65 70 75 80
Gly Asp Leu Glu Glu Ile Phe Leu His Pro Gly Glu Ser Val Ile Gln
85 90 95
Val Ser Gly Lys Tyr Lys Trp Tyr Leu Lys Lys Leu Val Phe Val Thr
100 105 110
Asp Lys Gly Arg Tyr Leu Ser Phe Gly Lys Asp Ser Gly Thr Ser Phe
115 120 125
Asn Ala Val Pro Leu His Pro Asn Thr Val Leu Arg Phe Ile Ser Gly
130 135 140
Arg Ser Gly Ser Leu Ile Asp Ala Ile Gly Leu His Trp Asp Val Tyr
145 150 155 160
Pro Thr Ser Cys Ser Arg Cys
165

<210> 80
<211> 22
<212> PRT
<213> Homo sapiens
<220>
<221> SITE
<222> (22)
<223> Xaa equals stop translation

<400> 80
Met Leu Ala Ala Leu Ala Cys Ser Trp Arg Leu Leu Ser Leu Gly Ala
1 5 10 15
His Ser Gly Arg Ala Xaa
20
<210> 81

MAILING ADDRESS OF SENDER

U.S. Patent No. 6,994,857

Finnegan, Henderson, Farabow,
Garrett & Dunner, L.L.P.
901 New York Avenue, N.W.
Washington, D.C. 20001-4413

MAR 19 2000

```

<211> 733
<212> DNA
<213> Homo sapiens

<400> 81
gggatccgga gcccaaattct tctgacaaaa ctcacacatg cccaccgtgc ccagcacctg      60
aattcgaggg tgcaccgtca gtcttcctct tccccccaaa acccaaggac accctcatga      120
tctcccgga tctgaggtc acatgcgtgg tggaggacgt aagccacgaa gacctgagg      180
tcaagttcaa ctggtacgtg gacggcgtgg aggtgcataa tgccaagaca aagccgcggg      240
aggagcagta caacagcacg taccgtgtgg tcagcgtcct caccgtcctg caccaggact      300
ggctgaatgg caaggagtac aagtgaagg tctccaaca agcctccca acccccatcg      360
agaaaaccat ctcaaagcc aaagggcagc cccgagaacc acaggtgtac accctgcccc      420
catcccgga tgagctgacc aagaaccagg tcagcctgac ctgcctggtc aaaggcttct      480
atccaagcga catcgccgtg gagtgggaga gcaatgggca gccggagAAC aactacaaga      540
ccacgcctcc cgtgctggac tccgacggct ccttcttct ctacagcaag ctcaccgtgg      600
acaagagcag gtggcagcag gggAACgtct tctcatgctc cgtgatgcat gaggctctgc      660
acaaccacta cagcagaag agcctctccc tgtctccggg taaatgagtg cgacggccgc      720
gactctagag gat

<210> 82
<211> 5
<212> PRT
<213> Artificial sequence
<220>
<221> misc_structure
<223> membrane proximal motif of class 1 cytokine receptors

<220>
<221> misc_feature
<222> (3)
<223> Xaa equals any

<400> 82
Trp Ser Xaa Trp Ser
  1           5

<210> 83
<211> 86
<212> DNA

```

MAILING ADDRESS OF SENDER

U.S. Patent No. 6,994,857

Finnegan, Henderson, Farabow,
Garrett & Dunner, L.L.P.
901 New York Avenue, N.W.
Washington, D.C. 20001-4413

13 2006

```

<213> Artificial Sequence
<220>
<221> primer_bind
<223> forward primer useful for generation of a synthetic gamma
activation site (GAS) containing promoter element

<400> 83
gcgccctcgag atttccccga aatctagatt tccccgaaat gatttccccg aaatgatttc      60
cccgaaatat ctgccatctc aattag                                             86

<210> 84
<211> 27
<212> DNA
<213> Artificial Sequence
<220>
<221> primer_bind
<223> reverse primer useful for generation of a synthetic gamma
activation site (GAS) containing promoter element

<400> 84
gcggcaagct ttttgcaaag cctaggc                                           27

<210> 85
<211> 271
<212> DNA
<213> Artificial Sequence
<220>
<221> misc_feature
<223> Synthetic GAS-SV40 promoter sequence

<400> 85
ctcgagattt ccccgaaatc tagatttccc cgaaatgatt tccccgaaat gatttccccg      60
aaatatctgc catctcaatt agtcagcaac catagtcccc cccctaactc cgcccatccc      120
gccctaact cgcgccagtt cgcgccattc tccgccccat ggctgactaa ttttttttat      180
ttatgcagag gccgaggccg cctcggcctc tgagctattc cagaagtagt gaggaggctt      240
ttttggaggc ctaggctttt gcaaaaagct t                                       271

<210> 86
<211> 32
<212> DNA
<213> Artificial Sequence
<220>
<221> primer_bind
<223> primer useful for generation of a EGR/SEAP reporter construct

<400> 86

```

MAILING ADDRESS OF SENDER

U.S. Patent No. 6,994,857

Finnegan, Henderson, Farabow,
Garrett & Dunner, L.L.P.
901 New York Avenue, N.W.
Washington, D.C. 20001-4413

MAR 13 2006

gcgctcgagg gatgacagcg atagaacccc gg	32
<210> 87	
<211> 31	
<212> DNA	
<213> Artificial Sequence	
<220>	
<221> primer_bind	
<223> primer useful for generation of a EGR/SEAP reporter construct	
<400> 87	
gcgaagcttc gcgactcccc ggatccgcct c	31
<210> 88	
<211> 12	
<212> DNA	
<213> Artificial Sequence	
<220>	
<221> misc_binding	
<223> NF-KB binding site	
<400> 88	
ggggactttc cc	12
<210> 89	
<211> 73	
<212> DNA	
<213> Artificial Sequence	
<220>	
<221> primer_bind	
<223> forward primer useful for generation of a vector containing the NF-KB promoter element	
<400> 89	
gcggcctcga ggggactttc ccggggactt tccggggact ttcggggact ttccatcctg	60
ccatctcaat tag	73
<210> 90	
<211> 256	
<212> DNA	
<213> Artificial Sequence	
<220>	
<221> misc_feature	
<223> Synthetic NF-KB/SV40 promoter	
<400> 90	
ctcgagggga ctttcccggg gactttccgg ggactttccg ggactttcca tctgccatct	60
caattagtca gcaaccatag tcccgccct aactccgcc atcccgcccc taactccgcc	120
cagttccgcc cattctccgc cccatggctg actaattttt tttatttatg cagaggccga	180

MAILING ADDRESS OF SENDER

U.S. Patent No. 6,994,857

Finnegan, Henderson, Farabow,
Garrett & Dunner, L.L.P.
901 New York Avenue, N.W.
Washington, D.C. 20001-4413

ggccgctcg gcctctgagc tattccagaa gtagtgagga ggcttttttg gaggcctagg 240
cttttgcaaa aagctt 256
--.

In the Claims

Col. 313, line 22, in claim 1(c), "amino and" should read -- amino --.

Col. 313, line 33, in claim 1(e), "or fragment thereof and albumin" should read -- or fragment thereof, and albumin --.

Col. 313, line 55, in claim 1(i), "proten" should read -- protein --.

Col. 316, line 17, in claim 22, "protein, or thereof" should read -- protein, or fragment thereof --.

MAILING ADDRESS OF SENDER

U.S. Patent No. 6,994,857

Finnegan, Henderson, Farabow,
Garrett & Dunner, L.L.P.
901 New York Avenue, N.W.
Washington, D.C. 20001-4413

UNITED STATES PATENT AND TRADEMARK OFFICE
CERTIFICATE OF CORRECTION

PATENT NO. 6,994,857

Page 1 of 46

APPLICATION NO.: 09/833,041

ISSUE DATE: February 7, 2006

INVENTOR(S): Craig A. Rosen, William A. Haseltine

It is hereby certified that an error or errors appear in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

Under item (60) (Related U.S. Application Data) of the title page, delete the text beginning with "Provisional application No. 60/229,358" to and ending "provisional application No. 60/256,931, filed on Dec. 1, 2000."

Under item (57) (ABSTRACT) of the title page, "disordrs" should read --disorders--.

On page 7, column 2, in the 8th reference, delete the text beginning with "Hershfield, M.S., et al.," to and ending "7185-7189 (1991)" and insert -- Hochuli, E., "Interferon Immunogenicity: Technical Evaluation of Interferon- α 2a," *Journal of Interferon and Cytokine Research* 17:S15-S21 (1997). --

On page 10, column 2, after the 9th reference (Nilsson, J., et al.), insert -- Nilsson, J. et al., "Heat-Mediated Activation of Affinity-Immobilized Taq DNA Polymerase," *BioTechniques* 22:744-751 (1997). --

In the Specification:

Col. 25 (Table 1), row HLDOU18, column Exemplary Identifier, "SEQ ID NO:73" should read -- SEQ ID NO:74 --.

Col. 27 (Table 1), row HWACB86, column Exemplary Identifier, "SEQ ID NO:74" should read -- SEQ ID NO:75 --.

Col. 27 (Table 1), row HCEGG08, column Exemplary Identifier, "SEQ ID NO:75" should read -- SEQ ID NO:76 --.

Col. 29 (Table 1), row HWHGZ51, column Exemplary Identifier, "SEQ ID NO:76" should read -- SEQ ID NO:77 --.

MAILING ADDRESS OF SENDER

U.S. Patent No. 6,994,857

Finnegan, Henderson, Farabow,
Garrett & Dunner, L.L.P.
901 New York Avenue, N.W.
Washington, D.C. 20001-4413

MAR 13 2006

Col. 29 (Table 1), row HDTAI21, column Exemplary Identifier, "SEQ ID NO:77" should read -- SEQ ID NO:78 --.

Col. 29 (Table 1), row HCNCA73, column Exemplary Identifier, "SEQ ID NO:78" should read -- SEQ ID NO:79 --.

Col. 29 (Table 1), row HNHFE71, column Exemplary Identifier, "SEQ ID NO:79" should read -- SEQ ID NO:80 --.

Col. 62, lines 38-39, "(SEQ ID NO:36)" should read -- (SEQ ID NO:72) --.

Col. 215, line 8, "(SEQ ID NO:36)" should read -- (SEQ ID NO:81) --.

Col. 236, line 42, "(SEQ ID NO: 37)" should read -- (SEQ ID NO:82) --.

Col. 237, line 47, "(SEQ ID NO:38)" should read -- (SEQ ID NO:83) --.

Col. 237, lines 53-54, "(SEQ ID NO:39)" should read -- (SEQ ID NO:84) --.

Col. 237, line 63, "(SEQ ID NO:40)" should read -- (SEQ ID NO:85) --.

Col. 240, line 55, "(SEQ ID NO:41)" should read -- (SEQ ID NO:86) --.

Col. 240, line 58, "(SEQ ID NO:42)" should read -- (SEQ ID NO:87) --.

Col. 243, line 9, "(SEQ ID NO:43)" should read -- (SEQ ID NO:88) --.

Col. 243, line 14, "(SEQ ID NO:44)" should read -- (SEQ ID NO:89) --.

Col. 243, lines 17-18, "(SEQ ID NO:39)" should read -- (SEQ ID NO:84) --.

Col. 243, line 28, "(SEQ ID NO:45)" should read -- (SEQ ID NO:90) --.

In the Sequence Listing:

Delete the Sequence Listing beginning in Col. 263, beginning with the text "<160> NUMBER OF SEQ ID NOS: 79" to and ending "Pro Thr Ser Cys Ser Arg Cys"

165

in Col. 313 and insert the following Sequence Listing:

-- <160> NUMBER OF SEQ ID NOS: 90

<210> 1

<211> 23

<212> DNA

<213> Artificial Sequence

MAILING ADDRESS OF SENDER

U.S. Patent No. 6,994,857

Finnegan, Henderson, Farabow,
Garrett & Dunner, L.L.P.
901 New York Avenue, N.W.
Washington, D.C. 20001-4413

MAR 13 2006

<220>
 <221> primer_bind
 <223> primer useful to clone human growth hormone cDNA

 <400> 1
 cccaagaatt cccttatcca ggc 23

 <210> 2
 <211> 33
 <212> DNA
 <213> Artificial Sequence
 <220>
 <221> primer_bind
 <223> primer useful to clone human growth hormone cDNA

 <400> 2
 gggaagctta gaagccacag gatccctcca cag 33

 <210> 3
 <211> 16
 <212> DNA
 <213> Artificial Sequence
 <220>
 <221> misc_structure
 <223> synthetic oligonucleotide used to join DNA fragments
 with non-cohesive ends.

 <400> 3
 gataaagatt cccaac 16

 <210> 4
 <211> 17
 <212> DNA
 <213> Artificial Sequence
 <220>
 <221> misc_structure
 <223> synthetic oligonucleotide used to join DNA fragments
 with non-cohesive ends.

 <400> 4
 aattgttggg aatcttt 17

 <210> 5
 <211> 17
 <212> DNA
 <213> Artificial Sequence
 <220>
 <221> misc_structure

MAILING ADDRESS OF SENDER

U.S. Patent No. 6,994,857

Finnegan, Henderson, Farabow,
 Garrett & Dunner, L.L.P.
 901 New York Avenue, N.W.
 Washington, D.C. 20001-4413

6 2006

<223> synthetic oligonucleotide used to join DNA fragments with non-cohesive ends.

<400> 5

ttaggcttat tcccaac

17

<210> 6

<211> 18

<212> DNA

<213> Artificial Sequence

<220>

<221> misc_structure

<223> synthetic oligonucleotide used to join DNA fragments with non-cohesive ends.

<400> 6

aattgttggg aataagcc

18

<210> 7

<211> 24

<212> PRT

<213> Artificial Sequence

<220>

<221> SITE

<222> 1)..(19)

<223> invertase leader sequence

<220>

<221> SITE

<222> 20)..(24)

<223> first 5 amino acids of mature human serum albumin

<400> 7

Met Leu Leu Gln Ala Phe Leu Phe Leu Leu Ala Gly Phe Ala Ala Lys
1 5 10 15

Ile Ser Ala Asp Ala His Lys Ser
20

<210> 8

<211> 21

<212> DNA

<213> Artificial Sequence

<220>

<221> misc_structure

<223> synthetic oligonucleotide used to join DNA fragments with non-cohesive ends.

<400> 8

gagatgcaca cctgagtgag g

21

MAILING ADDRESS OF SENDER

U.S. Patent No. 6,994,857

Finnegan, Henderson, Farabow,
Garrett & Dunner, L.L.P.
901 New York Avenue, N.W.
Washington, D.C. 20001-4413

MAR 13 2006

<210> 9
<211> 27
<212> DNA
<213> Artificial Sequence
<220>
<221> misc_structure
<223> synthetic oligonucleotide used to join DNA
fragments with non-cohesive ends.

<400> 9
gatcctgtgg cttcgatgca cacaaga

27

<210> 10
<211> 24
<212> DNA
<213> Artificial Sequence
<220>
<221> misc_structure
<223> synthetic oligonucleotide used to join DNA
fragments with non-cohesive ends.

<400> 10
ctcttgtgtg catcgaagcc acag

24

<210> 11
<211> 30
<212> DNA
<213> Artificial Sequence
<220>
<221> misc_structure
<223> synthetic oligonucleotide used to join DNA
fragments with non-cohesive ends.

<400> 11
tgtggaagag cctcagaatt tattcccaac

30

<210> 12
<211> 31
<212> DNA
<213> Artificial Sequence
<220>
<221> misc_structure
<223> synthetic oligonucleotide used to join DNA
fragments with non-cohesive ends.

<400> 12
aattgttggg aataaattct gaggtctttc c

31

MAILING ADDRESS OF SENDER

U.S. Patent No. 6,994,857

Finnegan, Henderson, Farabow,
Garrett & Dunner, L.L.P.
901 New York Avenue, N.W.
Washington, D.C. 20001-4413

MAR 13 2006

<210> 13
 <211> 47
 <212> DNA
 <213> Artificial Sequence
 <220>
 <221> misc_structure
 <223> synthetic oligonucleotide used to join DNA
 fragments with non-cohesive ends.

 <400> 13
 ttaggcttag gtggcggtgg atccggcggt ggtggatctt tcccaac

47

<210> 14
 <211> 48
 <212> DNA
 <213> Artificial Sequence
 <220>
 <221> misc_structure
 <223> synthetic oligonucleotide used to join DNA
 fragments with non-cohesive ends.

<400> 14
 aattgttggg aaagatccac caccgccgga tccaccgcca cctaagcc

48

<210> 15
 <211> 62
 <212> DNA
 <213> Artificial Sequence
 <220>
 <221> misc_structure
 <223> synthetic oligonucleotide used to join DNA
 fragments with non-cohesive ends.

<400> 15
 ttaggcttag gcggtggtgg atctggtggc ggcggatctg gtggcggtgg atccttccca
 ac

62

<210> 16
 <211> 63
 <212> DNA
 <213> Artificial Sequence
 <220>
 <221> misc_structure
 <223> synthetic oligonucleotide used to join DNA
 fragments with non-cohesive ends.

<400> 16
 aattgttggg aaggatccac cgccaccaga tccgccgcca ccagatccac caccgcctaa

60

MAILING ADDRESS OF SENDER

U.S. Patent No. 6,994,857

Finnegan, Henderson, Farabow,
 Garrett & Dunner, L.L.P.
 901 New York Avenue, N.W.
 Washington, D.C. 20001-4413

gcc

63

<210> 17

<211> 1782

<212> DNA

<213> Homo sapiens

<220>

<221> CDS

<222> (1)..(1755)

<400> 17

```

gat gca cac aag agt gag gtt gct cat cgg ttt aaa gat ttg gga gaa 48
Asp Ala His Lys Ser Glu Val Ala His Arg Phe Lys Asp Leu Gly Glu
  1           5           10           15

gaa aat ttc aaa gcc ttg gtg ttg att gcc ttt gct cag tat ctt cag 96
Glu Asn Phe Lys Ala Leu Val Leu Ile Ala Phe Ala Gln Tyr Leu Gln
          20           25           30

cag tgt cca ttt gaa gat cat gta aaa tta gtg aat gaa gta act gaa 144
Gln Cys Pro Phe Glu Asp His Val Lys Leu Val Asn Glu Val Thr Glu
        35           40           45

ttt gca aaa aca tgt gtt gct gat gag tca gct gaa aat tgt gac aaa 192
Phe Ala Lys Thr Cys Val Ala Asp Glu Ser Ala Glu Asn Cys Asp Lys
      50           55           60

tca ctt cat acc ctt ttt gga gac aaa tta tgc aca gtt gca act ctt 240
Ser Leu His Thr Leu Phe Gly Asp Lys Leu Cys Thr Val Ala Thr Leu
     65           70           75           80

cgt gaa acc tat ggt gaa atg gct gac tgc tgt gca aaa caa gaa cct 288
Arg Glu Thr Tyr Gly Glu Met Ala Asp Cys Cys Ala Lys Gln Glu Pro
        85           90           95

gag aga aat gaa tgc ttc ttg caa cac aaa gat gac aac cca aac ctc 336
Glu Arg Asn Glu Cys Phe Leu Gln His Lys Asp Asp Asn Pro Asn Leu
      100           105           110

ccc cga ttg gtg aga cca gag gtt gat gtg atg tgc act gct ttt cat 384
Pro Arg Leu Val Arg Pro Glu Val Asp Val Met Cys Thr Ala Phe His
      115           120           125

gac aat gaa gag aca ttt ttg aaa aaa tac tta tat gaa att gcc aga 432
Asp Asn Glu Glu Thr Phe Leu Lys Lys Tyr Leu Tyr Glu Ile Ala Arg
     130           135           140

aga cat cct tac ttt tat gcc ccg gaa ctc ctt ttc ttt gct aaa agg 480
Arg His Pro Tyr Phe Tyr Ala Pro Glu Leu Leu Phe Phe Ala Lys Arg
    145           150           155           160

```

MAILING ADDRESS OF SENDER

U.S. Patent No. 6,994,857

Finnegan, Henderson, Farabow,
 Garrett & Dunner, L.L.P.
 901 New York Avenue, N.W.
 Washington, D.C. 20001-4413

MAR 3 2006

tat aaa gct gct ttt aca gaa tgt tgc caa gct gct gat aaa gct gcc	528
Tyr Lys Ala Ala Phe Thr Glu Cys Cys Gln Ala Ala Asp Lys Ala Ala	
165 170 175	
tgc ctg ttg cca aag ctc gat gaa ctt cgg gat gaa ggg aag gct tcg	576
Cys Leu Leu Pro Lys Leu Asp Glu Leu Arg Asp Glu Gly Lys Ala Ser	
180 185 190	
tct gcc aaa cag aga ctc aaa tgt gcc agt ctc caa aaa ttt gga gaa	624
Ser Ala Lys Gln Arg Leu Lys Cys Ala Ser Leu Gln Lys Phe Gly Glu	
195 200 205	
aga gct ttc aaa gca tgg gca gtg gct cgc ctg agc cag aga ttt ccc	672
Arg Ala Phe Lys Ala Trp Ala Val Ala Arg Leu Ser Gln Arg Phe Pro	
210 215 220	
aaa gct gag ttt gca gaa gtt tcc aag tta gtg aca gat ctt acc aaa	720
Lys Ala Glu Phe Ala Glu Val Ser Lys Leu Val Thr Asp Leu Thr Lys	
225 230 235 240	
gtc cac acg gaa tgc tgc cat gga gat ctg ctt gaa tgt gct gat gac	768
Val His Thr Glu Cys Cys His Gly Asp Leu Leu Glu Cys Ala Asp Asp	
245 250 255	
agg gcg gac ctt gcc aag tat atc tgt gaa aat cag gat tcg atc tcc	816
Arg Ala Asp Leu Ala Lys Tyr Ile Cys Glu Asn Gln Asp Ser Ile Ser	
260 265 270	
agt aaa ctg aag gaa tgc tgt gaa aaa cct ctg ttg gaa aaa tcc cac	864
Ser Lys Leu Lys Glu Cys Cys Glu Lys Pro Leu Leu Glu Lys Ser His	
275 280 285	
tgc att gcc gaa gtg gaa aat gat gag atg cct gct gac ttg cct tca	912
Cys Ile Ala Glu Val Glu Asn Asp Glu Met Pro Ala Asp Leu Pro Ser	
290 295 300	
tta gct gct gat ttt gtt gaa agt aag gat gtt tgc aaa aac tat gct	960
Leu Ala Ala Asp Phe Val Glu Ser Lys Asp Val Cys Lys Asn Tyr Ala	
305 310 315 320	
gag gca aag gat gtc ttc ctg ggc atg ttt ttg tat gaa tat gca aga	1008
Glu Ala Lys Asp Val Phe Leu Gly Met Phe Leu Tyr Glu Tyr Ala Arg	
325 330 335	
agg cat cct gat tac tct gtc gtg ctg ctg ctg aga ctt gcc aag aca	1056
Arg His Pro Asp Tyr Ser Val Val Leu Leu Leu Arg Leu Ala Lys Thr	
340 345 350	
tat gaa acc act cta gag aag tgc tgt gcc gct gca gat cct cat gaa	1104
Tyr Glu Thr Thr Leu Glu Lys Cys Cys Ala Ala Ala Asp Pro His Glu	
355 360 365	

MAILING ADDRESS OF SENDER

U.S. Patent No. 6,994,857

Finnegan, Henderson, Farabow,
Garrett & Dunner, L.L.P.
901 New York Avenue, N.W.
Washington, D.C. 20001-4413

MAR 13 2006

tgc tat gcc aaa gtg ttc gat gaa ttt aaa cct ctt gtg gaa gag cct	1152
Cys Tyr Ala Lys Val Phe Asp Glu Phe Lys Pro Leu Val Glu Glu Pro	
370 375 380	
cag aat tta atc aaa caa aac tgt gag ctt ttt gag cag ctt gga gag	1200
Gln Asn Leu Ile Lys Gln Asn Cys Glu Leu Phe Glu Gln Leu Gly Glu	
385 390 395 400	
tac aaa ttc cag aat gcg cta tta gtt cgt tac acc aag aaa gta ccc	1248
Tyr Lys Phe Gln Asn Ala Leu Leu Val Arg Tyr Thr Lys Lys Val Pro	
405 410 415	
caa gtg tca act cca act ctt gta gag gtc tca aga aac cta gga aaa	1296
Gln Val Ser Thr Pro Thr Leu Val Glu Val Ser Arg Asn Leu Gly Lys	
420 425 430	
gtg ggc agc aaa tgt tgt aaa cat cct gaa gca aaa aga atg ccc tgt	1344
Val Gly Ser Lys Cys Cys Lys His Pro Glu Ala Lys Arg Met Pro Cys	
435 440 445	
gca gaa gac tat cta tcc gtg gtc ctg aac cag tta tgt gtg ttg cat	1392
Ala Glu Asp Tyr Leu Ser Val Val Leu Asn Gln Leu Cys Val Leu His	
450 455 460	
gag aaa acg cca gta agt gac aga gtc aca aaa tgc tgc aca gag tcc	1440
Glu Lys Thr Pro Val Ser Asp Arg Val Thr Lys Cys Cys Thr Glu Ser	
465 470 475 480	
ttg gtg aac agg cga cca tgc ttt tca gct ctg gaa gtc gat gaa aca	1488
Leu Val Asn Arg Arg Pro Cys Phe Ser Ala Leu Glu Val Asp Glu Thr	
485 490 495	
tac gtt ccc aaa gag ttt aat gct gaa aca ttc acc ttc cat gca gat	1536
Tyr Val Pro Lys Glu Phe Asn Ala Glu Thr Phe Thr Phe His Ala Asp	
500 505 510	
ata tgc aca ctt tct gag aag gag aga caa atc aag aaa caa act gca	1584
Ile Cys Thr Leu Ser Glu Lys Glu Arg Gln Ile Lys Lys Gln Thr Ala	
515 520 525	
ctt gtt gag ctt gtg aaa cac aag ccc aag gca aca aaa gag caa ctg	1632
Leu Val Glu Leu Val Lys His Lys Pro Lys Ala Thr Lys Glu Gln Leu	
530 535 540	
aaa gct gtt atg gat gat ttc gca gct ttt gta gag aag tgc tgc aag	1680
Lys Ala Val Met Asp Asp Phe Ala Ala Phe Val Glu Lys Cys Cys Lys	
545 550 555 560	
gct gac gat aag gag acc tgc ttt gcc gag gag ggt aaa aaa ctt gtt	1728
Ala Asp Asp Lys Glu Thr Cys Phe Ala Glu Glu Gly Lys Lys Leu Val	
565 570 575	

MAILING ADDRESS OF SENDER

U.S. Patent No. 6,994,857

Finnegan, Henderson, Farabow,
Garrett & Dunner, L.L.P.
901 New York Avenue, N.W.
Washington, D.C. 20001-4413

MAR 13 2006

gct gca agt caa gct gcc tta ggc tta taacatctac atttaaaagc atctcag 1782
 Ala Ala Ser Gln Ala Ala Leu Gly Leu
 580 585

<210> 18
 <211> 585
 <212> PRT
 <213> Homo Sapiens

<400> 18
 Asp Ala His Lys Ser Glu Val Ala His Arg Phe Lys Asp Leu Gly Glu
 1 5 10 15
 Glu Asn Phe Lys Ala Leu Val Leu Ile Ala Phe Ala Gln Tyr Leu Gln
 20 25 30
 Gln Cys Pro Phe Glu Asp His Val Lys Leu Val Asn Glu Val Thr Glu
 35 40 45
 Phe Ala Lys Thr Cys Val Ala Asp Glu Ser Ala Glu Asn Cys Asp Lys
 50 55 60
 Ser Leu His Thr Leu Phe Gly Asp Lys Leu Cys Thr Val Ala Thr Leu
 65 70 75 80
 Arg Glu Thr Tyr Gly Glu Met Ala Asp Cys Cys Ala Lys Gln Glu Pro
 85 90 95
 Glu Arg Asn Glu Cys Phe Leu Gln His Lys Asp Asp Asn Pro Asn Leu
 100 105 110
 Pro Arg Leu Val Arg Pro Glu Val Asp Val Met Cys Thr Ala Phe His
 115 120 125
 Asp Asn Glu Glu Thr Phe Leu Lys Lys Tyr Leu Tyr Glu Ile Ala Arg
 130 135 140
 Arg His Pro Tyr Phe Tyr Ala Pro Glu Leu Leu Phe Phe Ala Lys Arg
 145 150 155 160
 Tyr Lys Ala Ala Phe Thr Glu Cys Cys Gln Ala Ala Asp Lys Ala Ala
 165 170 175
 Cys Leu Leu Pro Lys Leu Asp Glu Leu Arg Asp Glu Gly Lys Ala Ser
 180 185 190
 Ser Ala Lys Gln Arg Leu Lys Cys Ala Ser Leu Gln Lys Phe Gly Glu
 195 200 205
 Arg Ala Phe Lys Ala Trp Ala Val Ala Arg Leu Ser Gln Arg Phe Pro
 210 215 220

MAILING ADDRESS OF SENDER

U.S. Patent No. 6,994,857

Finnegan, Henderson, Farabow,
 Garrett & Dunner, L.L.P.
 901 New York Avenue, N.W.
 Washington, D.C. 20001-4413

MAR 13 2006

Lys	Ala	Glu	Phe	Ala	Glu	Val	Ser	Lys	Leu	Val	Thr	Asp	Leu	Thr	Lys	225	230	235	240
Val	His	Thr	Glu	Cys	Cys	His	Gly	Asp	Leu	Leu	Glu	Cys	Ala	Asp	Asp	245	250	255	
Arg	Ala	Asp	Leu	Ala	Lys	Tyr	Ile	Cys	Glu	Asn	Gln	Asp	Ser	Ile	Ser	260	265	270	
Ser	Lys	Leu	Lys	Glu	Cys	Cys	Glu	Lys	Pro	Leu	Leu	Glu	Lys	Ser	His	275	280	285	
Cys	Ile	Ala	Glu	Val	Glu	Asn	Asp	Glu	Met	Pro	Ala	Asp	Leu	Pro	Ser	290	295	300	
Leu	Ala	Ala	Asp	Phe	Val	Glu	Ser	Lys	Asp	Val	Cys	Lys	Asn	Tyr	Ala	305	310	315	320
Glu	Ala	Lys	Asp	Val	Phe	Leu	Gly	Met	Phe	Leu	Tyr	Glu	Tyr	Ala	Arg	325	330	335	
Arg	His	Pro	Asp	Tyr	Ser	Val	Val	Leu	Leu	Leu	Arg	Leu	Ala	Lys	Thr	340	345	350	
Tyr	Glu	Thr	Thr	Leu	Glu	Lys	Cys	Cys	Ala	Ala	Ala	Asp	Pro	His	Glu	355	360	365	
Cys	Tyr	Ala	Lys	Val	Phe	Asp	Glu	Phe	Lys	Pro	Leu	Val	Glu	Glu	Pro	370	375	380	
Gln	Asn	Leu	Ile	Lys	Gln	Asn	Cys	Glu	Leu	Phe	Glu	Gln	Leu	Gly	Glu	385	390	395	400
Tyr	Lys	Phe	Gln	Asn	Ala	Leu	Leu	Val	Arg	Tyr	Thr	Lys	Lys	Val	Pro	405	410	415	
Gln	Val	Ser	Thr	Pro	Thr	Leu	Val	Glu	Val	Ser	Arg	Asn	Leu	Gly	Lys	420	425	430	
Val	Gly	Ser	Lys	Cys	Cys	Lys	His	Pro	Glu	Ala	Lys	Arg	Met	Pro	Cys	435	440	445	
Ala	Glu	Asp	Tyr	Leu	Ser	Val	Val	Leu	Asn	Gln	Leu	Cys	Val	Leu	His	450	455	460	
Glu	Lys	Thr	Pro	Val	Ser	Asp	Arg	Val	Thr	Lys	Cys	Cys	Thr	Glu	Ser	465	470	475	480
Leu	Val	Asn	Arg	Arg	Pro	Cys	Phe	Ser	Ala	Leu	Glu	Val	Asp	Glu	Thr	485	490	495	

MAILING ADDRESS OF SENDER

U.S. Patent No. 6,994,857

Finnegan, Henderson, Farabow,
Garrett & Dunner, L.L.P.
901 New York Avenue, N.W.
Washington, D.C. 20001-4413

MAR 13 2006

Tyr Val Pro Lys Glu Phe Asn Ala Glu Thr Phe Thr Phe His Ala Asp
500 505 510

Ile Cys Thr Leu Ser Glu Lys Glu Arg Gln Ile Lys Lys Gln Thr Ala
515 520 525

Leu Val Glu Leu Val Lys His Lys Pro Lys Ala Thr Lys Glu Gln Leu
530 535 540

Lys Ala Val Met Asp Asp Phe Ala Ala Phe Val Glu Lys Cys Cys Lys
545 550 555 560

Ala Asp Asp Lys Glu Thr Cys Phe Ala Glu Glu Gly Lys Lys Leu Val
565 570 575

Ala Ala Ser Gln Ala Ala Leu Gly Leu
580 585

<210> 19

<211> 58

<212> DNA

<213> Artificial Sequence

<220>

<221> primer_bind

<223> primer used to generate XhoI and ClaI
site in pPPC0006

<400> 19

gcctcgagaa aagagatgca cacaagagtg aggttgctca tcgatttaaa gatttggg 58

<210> 20

<211> 59

<212> DNA

<213> Artificial Sequence

<220>

<221> primer_bind

<223> primer used in generation XhoI and ClaI
site in pPPC0006

<400> 20

aatcgatgag caacctcact cttgtgtgca tctcttttct cgaggctcct ggaataagc 59

<210> 21

<211> 24

<212> DNA

<213> Artificial Sequence

<220>

<221> primer_bind

<223> primer used in generation XhoI and ClaI

MAILING ADDRESS OF SENDER

U.S. Patent No. 6,994,857

Finnegan, Henderson, Farabow,
Garrett & Dunner, L.L.P.
901 New York Avenue, N.W.
Washington, D.C. 20001-4413

MAR 13 2000

site in pPPC0006

<400> 21

tacaaactta agagtccaat tagc

24

<210> 22

<211> 29

<212> DNA

<213> Artificial Sequence

<220>

<221> primer_bind

<223> primer used in generation XhoI and ClaI
site in pPPC0006

<400> 22

cacttctcta gagtggtttc atatgtctt

29

<210> 23

<211> 60

<212> DNA

<213> Artificial Sequence

<220>

<221> Misc_Structure

<223> Synthetic oligonucleotide used to alter restriction
sites in pPPC0007

<400> 23

aagctgcctt aggcttataa taaggcgcg cggccggccg tttaaactaa gcttaattct 60

<210> 24

<211> 60

<212> DNA

<213> Artificial Sequence

<220>

<221> Misc_Structure

<223> Synthetic oligonucleotide used to alter restriction
sites in pPPC0007

<400> 24

agaattaagc ttagtttaaa cggccggccg gcgcgcctta ttataagcct aaggcagctt 60

<210> 25

<211> 32

<212> DNA

<213> Artificial Sequence

<220>

<221> primer_bind

<223> forward primer useful for generation of albumin

MAILING ADDRESS OF SENDER

U.S. Patent No. 6,994,857

Finnegan, Henderson, Farabow,
Garrett & Dunner, L.L.P.
901 New York Avenue, N.W.
Washington, D.C. 20001-4413

fusion protein in which the albumin moiety is N-terminal
of the Therapeutic Protein

<220>
<221> misc_feature
<222> (18)
<223> n equals a,t,g, or c

<220>
<221> misc_feature
<222> (19)
<223> n equals a,t,g, or c

<220>
<221> misc_feature
<222> (20)
<223> n equals a,t,g, or c

<220>
<221> misc_feature
<222> (21)
<223> n equals a,t,g, or c

<220>
<221> misc_feature
<222> (22)
<223> n equals a,t,g, or c

<220>
<221> misc_feature
<222> (23)
<223> n equals a,t,g, or c

<220>
<221> misc_feature
<222> (24)
<223> n equals a,t,g, or c

<220>
<221> misc_feature
<222> (25)
<223> n equals a,t,g, or c

<220>
<221> misc_feature
<222> (26)
<223> n equals a,t,g, or c

<220>
<221> misc_feature
<222> (27)

MAILING ADDRESS OF SENDER

U.S. Patent No. 6,994,857

Finnegan, Henderson, Farabow,
Garrett & Dunner, L.L.P.
901 New York Avenue, N.W.
Washington, D.C. 20001-4413

<223> n equals a,t,g, or c

<220>

<221> misc_feature

<222> (28)

<223> n equals a,t,g, or c

<220>

<221> misc_feature

<222> (29)

<223> n equals a,t,g, or c

<220>

<221> misc_feature

<222> (30)

<223> n equals a,t,g, or c

<220>

<221> misc_feature

<222> (31)

<223> n equals a,t,g, or c

<220>

<221> misc_feature

<222> (32)

<223> n equals a,t,g, or c

<400> 25

aagctgcctt aggcttannn nnnnnnnnnn nn

32

<210> 26

<211> 51

<212> DNA

<213> Artificial Sequence

<220>

<221> primer_bind

<223> reverse primer useful for generation of albumin
fusion protein in which the albumin moiety is N-terminal
of the Therapeutic Protein

<220>

<221> misc_feature

<222> (37)

<223> n equals a,t,g, or c

<220>

<221> misc_feature

<222> (38)

<223> n equals a,t,g, or c

<220>

<221> misc_feature

<222> (39)

MAILING ADDRESS OF SENDER

U.S. Patent No. 6,994,857

Finnegan, Henderson, Farabow,
Garrett & Dunner, L.L.P.
901 New York Avenue, N.W.
Washington, D.C. 20001-4413

MAR 13 2006

<223> n equals a,t,g, or c

<220>

<221> misc_feature

<222> (40)

<223> n equals a,t,g, or c

<220>

<221> misc_feature

<222> (41)

<223> n equals a,t,g, or c

<220>

<221> misc_feature

<222> (42)

<223> n equals a,t,g, or c

<220>

<221> misc_feature

<222> (43)

<223> n equals a,t,g, or c

<220>

<221> misc_feature

<222> (44)

<223> n equals a,t,g, or c

<220>

<221> misc_feature

<222> (45)

<223> n equals a,t,g, or c

<220>

<221> misc_feature

<222> (46)

<223> n equals a,t,g, or c

<220>

<221> misc_feature

<222> (47)

<223> n equals a,t,g, or c

<220>

<221> misc_feature

<222> (48)

<223> n equals a,t,g, or c

<220>

<221> misc_feature

<222> (49)

<223> n equals a,t,g, or c

MAILING ADDRESS OF SENDER

U.S. Patent No. 6,994,857

Finnegan, Henderson, Farabow,
Garrett & Dunner, L.L.P.
901 New York Avenue, N.W.
Washington, D.C. 20001-4413

MAR 13 2006

<220>
<221> misc_feature
<222> (50)
<223> n equals a,t,g, or c

<220>
<221> misc_feature
<222> (51)
<223> n equals a,t,g, or c

<400> 26
gcgcgcgttt aaacggccgg ccggcgcgcc ttattannnn nnnnnnnnnn n 51

<210> 27
<211> 33
<212> DNA
<213> Artificial Sequence

<220>
<223> forward primer useful for generation of albumin fusion protein in which the albumin moiety is c-terminal of the Therapeutic Protein

<220>
<221> misc_feature
<222> (19)
<223> n equals a,t,g, or c

<220>
<221> misc_feature
<222> (20)
<223> n equals a,t,g, or c

<220>
<221> misc_feature
<222> (21)
<223> n equals a,t,g, or c

<220>
<221> misc_feature
<222> (22)
<223> n equals a,t,g, or c

<220>
<221> misc_feature
<222> (23)
<223> n equals a,t,g, or c

<220>
<221> misc_feature
<222> (24)
<223> n equals a,t,g, or c

MAILING ADDRESS OF SENDER

U.S. Patent No. 6,994,857

Finnegan, Henderson, Farabow,
Garrett & Dunner, L.L.P.
901 New York Avenue, N.W.
Washington, D.C. 20001-4413

MAR 13 2006

```

<220>
<221> misc_feature
<222> (25)
<223> n equals a,t,g, or c

<220>
<221> misc_feature
<222> (26)
<223> n equals a,t,g, or c

<220>
<221> misc_feature
<222> (27)
<223> n equals a,t,g, or c

<220>
<221> misc_feature
<222> (28)
<223> n equals a,t,g, or c

<220>
<221> misc_feature
<222> (29)
<223> n equals a,t,g, or c

<220>
<221> misc_feature
<222> (30)
<223> n equals a,t,g, or c

<220>
<221> misc_feature
<222> (31)
<223> n equals a,t,g, or c

<220>
<221> misc_feature
<222> (32)
<223> n equals a,t,g, or c

<220>
<221> misc_feature
<222> (33)
<223> n equals a,t,g, or c

<400> 27
aggagcgtcg acaaaagann nnnnnnnnnn nnn

<210> 28
<211> 52
<212> DNA

```

33

MAILING ADDRESS OF SENDER

U.S. Patent No. 6,994,857

Finnegan, Henderson, Farabow,
Garrett & Dunner, L.L.P.
901 New York Avenue, N.W.
Washington, D.C. 20001-4413

MAR 18 2006

<213> Artificial Sequence
<220>
<221> primer_bind
<223> reverse primer useful for generation of albumin
fusion protein in which the albumin moiety is c-terminal of
the Therapeutic Protein

<220>
<221> misc_feature
<222> (38)
<223> n equals a,t,g, or c

<220>
<221> misc_feature
<222> (39)
<223> n equals a,t,g, or c

<220>
<221> misc_feature
<222> (40)
<223> n equals a,t,g, or c

<220>
<221> misc_feature
<222> (41)
<223> n equals a,t,g, or c

<220>
<221> misc_feature
<222> (42)
<223> n equals a,t,g, or c

<220>
<221> misc_feature
<222> (43)
<223> n equals a,t,g, or c

<220>
<221> misc_feature
<222> (44)
<223> n equals a,t,g, or c

<220>
<221> misc_feature
<222> (45)
<223> n equals a,t,g, or c

<220>
<221> misc_feature
<222> (46)
<223> n equals a,t,g, or c

MAILING ADDRESS OF SENDER

U.S. Patent No. 6,994,857

Finnegan, Henderson, Farabow,
Garrett & Dunner, L.L.P.
901 New York Avenue, N.W.
Washington, D.C. 20001-4413

<220>
<221> misc_feature
<222> (47)
<223> n equals a,t,g, or c

<220>
<221> misc_feature
<222> (48)
<223> n equals a,t,g, or c

<220>
<221> misc_feature
<222> (49)
<223> n equals a,t,g, or c

<220>
<221> misc_feature
<222> (50)
<223> n equals a,t,g, or c

<220>
<221> misc_feature
<222> (51)
<223> n equals a,t,g, or c

<220>
<221> misc_feature
<222> (52)
<223> n equals a,t,g, or c

<400> 28
ctttaaactcg atgagcaacc tcactcttgt gtgcatcnnn nnnnnnnnnn nn

52

<210> 29
<211> 24
<212> PRT
<213> Artificial Sequence
<220>
<221> signal
<223> signal peptide of natural human serum albumin protein

<400> 29
Met Lys Trp Val Ser Phe Ile Ser Leu Leu Phe Leu Phe Ser Ser Ala
1 5 10 15

Tyr Ser Arg Ser Leu Asp Lys Arg
20

<210> 30
<211> 114
<212> DNA

MAILING ADDRESS OF SENDER

U.S. Patent No. 6,994,857

Finnegan, Henderson, Farabow,
Garrett & Dunner, L.L.P.
901 New York Avenue, N.W.
Washington, D.C. 20001-4413

MAR 13 2006

```

<213> Artificial Sequence

<220>
<221> primer_bind
<223> forward primer useful for generation of PC4:HSA
albumin fusion VECTOR

<220>
<221> misc_feature
<222> (5)..(10)
<223> BamHI restriction site

<220>
<221> misc_feature
<222> (11)..(16)
<223> Hind III restriction site

<220>
<221> misc_feature
<222> (17)..(27)
<223> Kozak sequence

<220>
<221> misc_feature
<222> (25)..(97)
<223> cds natural signal sequence of human serum albumin

<220>
<221> misc_feature
<222> (75)..(81)
<223> XhoI restriction site

<220>
<221> misc_feature
<222> (98)..(114)
<223> cds first six amino acids of human serum albumin

<400> 30
tcagggatcc aagcttcgc caccatgaag tgggtaacct ttatttcctc tctttttctc 60

tttagctcgg cttagctgag ggggtgtgtt cgtcgagatg cacacaagag tgag      114

<210> 31
<211> 43
<212> DNA
<213> Artificial Sequence

<220>
<221> primer_bind
<223> reverse primer useful for generation of
PC4:HSA albumin fusion VECTOR

```

MAILING ADDRESS OF SENDER

U.S. Patent No. 6,994,857

Finnegan, Henderson, Farabow,
Garrett & Dunner, L.L.P.
901 New York Avenue, N.W.
Washington, D.C. 20001-4413

7/27/06 18:20:06

```

<220>
<221> misc_feature
<222> (6)..(11)
<223> Asp718 restriction site

<220>
<221> misc_feature
<222> (12)..(17)
<223> EcoRI restriction site

<220>
<221> misc_feature
<222> (15)..(17)
<223> reverse complement of stop codon

<220>
<221> misc_feature
<222> (18)..(25)
<223> AscI restriction site

<220>
<221> misc_feature
<222> (18)..(43)
<223> reverse complement of DNA sequence encoding last 9 amino acids

<400> 31
gcagcgggtac cgaattcggc gcgccttata agcctaaggc agc
43

<210> 32
<211> 46
<212> DNA
<213> Artificial Sequence
<220>
<221> primer_bind
<223> forward primer useful for inserting Therapeutic
protein into pC4:HSA vector

<220>
<221> misc_feature
<222> (29)
<223> n equals a,t,g, or c

<220>
<221> misc_feature
<222> (30)
<223> n equals a,t,g, or c

<220>
<221> misc_feature
<222> (31)
<223> n equals a,t,g, or c

```

MAILING ADDRESS OF SENDER

U.S. Patent No. 6,994,857

Finnegan, Henderson, Farabow,
Garrett & Dunner, L.L.P.
901 New York Avenue, N.W.
Washington, D.C. 20001-4413

<220>
<221> misc_feature
<222> (32)
<223> n equals a,t,g, or c

<220>
<221> misc_feature
<222> (33)
<223> n equals a,t,g, or c

<220>
<221> misc_feature
<222> (34)
<223> n equals a,t,g, or c

<220>
<221> misc_feature
<222> (35)
<223> n equals a,t,g, or c

<220>
<221> misc_feature
<222> (36)
<223> n equals a,t,g, or c

<220>
<221> misc_feature
<222> (37)
<223> n equals a,t,g, or c

<220>
<221> misc_feature
<222> (38)
<223> n equals a,t,g, or c

<220>
<221> misc_feature
<222> (39)
<223> n equals a,t,g, or c

<220>
<221> misc_feature
<222> (40)
<223> n equals a,t,g, or c

<220>
<221> misc_feature
<222> (41)
<223> n equals a,t,g, or c

<220>
<221> misc_feature

MAILING ADDRESS OF SENDER

U.S. Patent No. 6,994,857

Finnegan, Henderson, Farabow,
Garrett & Dunner, L.L.P.
901 New York Avenue, N.W.
Washington, D.C. 20001-4413

MAR 13 2006


```

<222> (42)
<223> n equals a,t,g, or c

<220>
<221> misc_feature
<222> (43)
<223> n equals a,t,g, or c

<220>
<221> misc_feature
<222> (44)
<223> n equals a,t,g, or c

<220>
<221> misc_feature
<222> (45)
<223> n equals a,t,g, or c

<220>
<221> misc_feature
<222> (46)
<223> n equals a,t,g, or c

<400> 32
ccgccgctcg aggggtgtgt ttctcgann nnnnnnnnnn nnnnnn

<210> 33
<211> 55
<212> DNA
<213> Artificial Sequence
<220>
<221> primer_bind
<223> reverse primer useful for inserting Therapeutic
protein into pC4:HSA vector

<220>
<221> misc_feature
<222> (38)
<223> n equals a,t,g, or c

<220>
<221> misc_feature
<222> (39)
<223> n equals a,t,g, or c

<220>
<221> misc_feature
<222> (40)
<223> n equals a,t,g, or c

<220>
<221> misc_feature

```

46

MAILING ADDRESS OF SENDER

U.S. Patent No. 6,994,857

Finnegan, Henderson, Farabow,
Garrett & Dunner, L.L.P.
901 New York Avenue, N.W.
Washington, D.C. 20001-4413

MAR 13 2006

<222> (41)
<223> n equals a,t,g, or c

<220>
<221> misc_feature
<222> (42)
<223> n equals a,t,g, or c

<220>
<221> misc_feature
<222> (43)
<223> n equals a,t,g, or c

<220>
<221> misc_feature
<222> (44)
<223> n equals a,t,g, or c

<220>
<221> misc_feature
<222> (45)
<223> n equals a,t,g, or c

<220>
<221> misc_feature
<222> (46)
<223> n equals a,t,g, or c

<220>
<221> misc_feature
<222> (47)
<223> n equals a,t,g, or c

<220>
<221> misc_feature
<222> (48)
<223> n equals a,t,g, or c

<220>
<221> misc_feature
<222> (49)
<223> n equals a,t,g, or c

<220>
<221> misc_feature
<222> (50)
<223> n equals a,t,g, or c

<220>
<221> misc_feature
<222> (51)

MAILING ADDRESS OF SENDER

U.S. Patent No. 6,994,857

Finnegan, Henderson, Farabow,
Garrett & Dunner, L.L.P.
901 New York Avenue, N.W.
Washington, D.C. 20001-4413

MAR 13 2006

<223> n equals a,t,g, or c

<220>

<221> misc_feature

<222> (52)

<223> n equals a,t,g, or c

<220>

<221> misc_feature

<222> (53)

<223> n equals a,t,g, or c

<220>

<221> misc_feature

<222> (54)

<223> n equals a,t,g, or c

<220>

<221> misc_feature

<222> (55)

<223> n equals a,t,g, or c

<400> 33

agtcccatcg atgagcaacc tcactcttgt gtgcacnnn nnnnnnnnnn nnnnn 55

<210> 34

<211> 17

<212> PRT

<213> Artificial Sequence

<220>

<221> signal

<223> Stanniocalcin signal peptide

<400> 34

Met	Leu	Gln	Asn	Ser	Ala	Val	Leu	Leu	Leu	Leu	Val	Ile	Ser	Ala	Ser
1				5					10					15	

Ala

<210> 35

<211> 22

<212> PRT

<213> Artificial Sequence

<220>

<221> signal

<223> Synthetic signal peptide

<400> 35

Met	Pro	Thr	Trp	Ala	Trp	Trp	Leu	Phe	Leu	Val	Leu	Leu	Leu	Ala	Leu
1				5				10						15	

MAILING ADDRESS OF SENDER

U.S. Patent No. 6,994,857

Finnegan, Henderson, Farabow,
Garrett & Dunner, L.L.P.
901 New York Avenue, N.W.
Washington, D.C. 20001-4413

MAR 13 2006

Trp Ala Pro Ala Arg Gly
20

<210> 36
<211> 23
<212> DNA
<213> Artificial Sequence
<220>
<221>primer_bind
<223>Degenerate VH forward primer useful for
amplifying human VH domains

<400> 36
caggtgcagc tgggtgcagtc tgg

23

<210> 37
<211> 23
<212> DNA
<213> Artificial Sequence
<220>
<221>primer_bind
<223>Degenerate VH forward primer useful for
amplifying human VH domains

<400> 37
caggtcaact taaggagtc tgg

23

<210> 38
<211> 23
<212> DNA
<213> Artificial Sequence
<220>
<221>primer_bind
<223>Degenerate VH forward primer useful for
amplifying human VH domains

<400> 38
gaggtgcagc tgggtggagtc tgg

23

<210> 39
<211> 23
<212> DNA
<213> Artificial Sequence
<220>
<221>primer_bind
<223>Degenerate VH forward primer useful for
amplifying human VH domains

<400> 39

MAILING ADDRESS OF SENDER

U.S. Patent No. 6,994,857

Finnegan, Henderson, Farabow,
Garrett & Dunner, L.L.P.
901 New York Avenue, N.W.
Washington, D.C. 20001-4413

MAR 13 2006

caggtgcagc tgcaggagtc ggg

23

<210> 40

<211> 23

<212> DNA

<213> Artificial Sequence

<220>

<221>primer_bind

<223>Degenerate VH forward primer useful for
amplifying human VH domains

<400> 40

gaggtgcagc tgttgcagtc tgc

23

<210> 41

<211> 23

<212> DNA

<213> Artificial Sequence

<220>

<221>primer_bind

<223>Degenerate VH forward primer useful for
amplifying human VH domains

<400> 41

caggtacagc tgcagcagtc agg

23

<210> 42

<211> 24

<212> DNA

<213> Artificial Sequence

<220>

<221>primer_bind

<223>Degenerate JH reverse primer useful for
amplifying human VH domains

<400> 42

tgaggagacg gtgaccaggg tgcc

24

<210> 43

<211> 24

<212> DNA

<213> Artificial Sequence

<220>

<221>primer_bind

<223>Degenerate JH reverse primer useful for
amplifying human VH domains

<400> 43

tgaagagacg gtgaccattg tccc

24

<210> 44

MAILING ADDRESS OF SENDER

U.S. Patent No. 6,994,857

Finnegan, Henderson, Farabow,
Garrett & Dunner, L.L.P.
901 New York Avenue, N.W.
Washington, D.C. 20001-4413

MAR 13 2006

<211> 24
 <212> DNA
 <213> Artificial Sequence
 <220>
 <221>primer_bind
 <223>Degenerate JH reverse primer useful for
 amplifying human VH domains

 <400> 44
 tgaggagacg gtgaccaggg ttcc 24

 <210> 45
 <211> 24
 <212> DNA
 <213> Artificial Sequence
 <220>
 <221>primer_bind
 <223>Degenerate JH reverse primer useful for
 amplifying human VH domains

 <400> 45
 tgaggagacg gtgaccgtgg tccc 24

 <210> 46
 <211> 23
 <212> DNA
 <213> Artificial Sequence
 <220>
 <221>primer_bind
 <223>Degenerate Vkappa forward primer useful for
 amplifying human VL domains

 <400> 46
 gacatccaga tgacccagtc tcc 23

 <210> 47
 <211> 23
 <212> DNA
 <213> Artificial Sequence
 <220>
 <221>primer_bind
 <223>Degenerate Vkappa forward primer useful for
 amplifying human VL domains

 <400> 47
 gatgttgatga tgactcagtc tcc 23

 <210> 48
 <211> 23
 <212> DNA
 <213> Artificial Sequence
 <220>

MAILING ADDRESS OF SENDER

U.S. Patent No. 6,994,857

Finnegan, Henderson, Farabow,
 Garrett & Dunner, L.L.P.
 901 New York Avenue, N.W.
 Washington, D.C. 20001-4413

MAR 13 2006

<221>primer_bind
 <223>Degenerate Vkappa forward primer useful for
 amplifying human VL domains

<400> 48
 gatattgtga tgactcagtc tcc 23

<210> 49
 <211> 23
 <212> DNA
 <213> Artificial Sequence
 <220>
 <221>primer_bind
 <223>Degenerate Vkappa forward primer useful for
 amplifying human VL domains

<400> 49
 gaaattgtgt tgacgcagtc tcc 23

<210> 50
 <211> 23
 <212> DNA
 <213> Artificial Sequence
 <220>
 <221>primer_bind
 <223>Degenerate Vkappa forward primer useful for
 amplifying human VL domains

<400> 50
 gacatcgtga tgacccagtc tcc 23

<210> 51
 <211> 23
 <212> DNA
 <213> Artificial Sequence
 <220>
 <221>primer_bind
 <223>Degenerate Vkappa forward primer useful for
 amplifying human VL domains

<400> 51
 gaaacgacac tcacgcagtc tcc 23

<210> 52
 <211> 23
 <212> DNA
 <213> Artificial Sequence
 <220>
 <221>primer_bind
 <223>Degenerate Vkappa forward primer useful for
 amplifying human VL domains

MAILING ADDRESS OF SENDER

U.S. Patent No. 6,994,857

Finnegan, Henderson, Farabow,
 Garrett & Dunner, L.L.P.
 901 New York Avenue, N.W.
 Washington, D.C. 20001-4413

<400> 52	
gaaattgtgc tgactcagtc tcc	23
<210> 53	
<211> 23	
<212> DNA	
<213> Artificial Sequence	
<220>	
<221>primer_bind	
<223>Degenerate Vlambda forward primer useful for amplifying human VL domains	
<400> 53	
cagtctgtgt tgacgcagcc gcc	23
<210> 54	
<211> 23	
<212> DNA	
<213> Artificial Sequence	
<220>	
<221>primer_bind	
<223>Degenerate Vlambda forward primer useful for amplifying human VL domains	
<400> 54	
cagtctgccc tgactcagcc tgc	23
<210> 55	
<211> 23	
<212> DNA	
<213> Artificial Sequence	
<220>	
<221>primer_bind	
<223>Degenerate Vlambda forward primer useful for amplifying human VL domains	
<400> 55	
tcctatgtgc tgactcagcc acc	23
<210> 56	
<211> 23	
<212> DNA	
<213> Artificial Sequence	
<220>	
<221>primer_bind	
<223>Degenerate Vlambda forward primer useful for amplifying human VL domains	
<400> 56	
tcttctgagc tgactcagga ccc	23
<210> 57	

MAILING ADDRESS OF SENDER

U.S. Patent No. 6,994,857

Finnegan, Henderson, Farabow,
Garrett & Dunner, L.L.P.
901 New York Avenue, N.W.
Washington, D.C. 20001-4413

MAR 13 2006

<211> 23	
<212> DNA	
<213> Artificial Sequence	
<220>	
<221>primer_bind	
<223>Degenerate Vlambda forward primer useful for amplifying human VL domains	
<400> 57	
cacgttatac tgactcaacc gcc	23
<210> 58	
<211> 23	
<212> DNA	
<213> Artificial Sequence	
<220>	
<221>primer_bind	
<223>Degenerate Vlambda forward primer useful for amplifying human VL domains	
<400> 58	
caggctgtgc tcaactcagcc gtc	23
<210> 59	
<211> 23	
<212> DNA	
<213> Artificial Sequence	
<220>	
<221>primer_bind	
<223>Degenerate Vlambda forward primer useful for amplifying human VL domains	
<400> 59	
aattttatgc tgactcagcc cca	23
<210> 60	
<211> 24	
<212> DNA	
<213> Artificial Sequence	
<220>	
<221>primer_bind	
<223>Degenerate Jkappa reverse primer useful for amplifying human VL domains	
<400> 60	
acgtttgatt tccaccttgg tccc	24
<210> 61	
<211> 24	
<212> DNA	
<213> Artificial Sequence	
<220>	

MAILING ADDRESS OF SENDER

U.S. Patent No. 6,994,857

Finnegan, Henderson, Farabow,
Garrett & Dunner, L.L.P.
901 New York Avenue, N.W.
Washington, D.C. 20001-4413

MAR 13 2006

<221>primer_bind
 <223>Degenerate Jkappa reverse primer useful for
 amplifying human VL domains

<400> 61
 acgtttgatc tccagcttgg tccc 24

<210> 62
 <211> 24
 <212> DNA
 <213> Artificial Sequence
 <220>
 <221>primer_bind
 <223>Degenerate Jkappa reverse primer useful for
 amplifying human VL domains

<400> 62
 acgtttgata tccactttgg tccc 24

<210> 63
 <211> 24
 <212> DNA
 <213> Artificial Sequence
 <220>
 <221>primer_bind
 <223>Degenerate Jkappa reverse primer useful for
 amplifying human VL domains

<400> 63
 acgtttgatc tccaccttgg tccc 24

<210> 64
 <211> 24
 <212> DNA
 <213> Artificial Sequence
 <220>
 <221>primer_bind
 <223>Degenerate Jkappa reverse primer useful for
 amplifying human VL domains

<400> 64
 acgtttaatc tccagtcgtg tccc 24

<210> 65
 <211> 23
 <212> DNA
 <213> Artificial Sequence
 <220>
 <221>primer_bind
 <223>Degenerate Jlambda reverse primer useful for
 amplifying human VL domains

MAILING ADDRESS OF SENDER

U.S. Patent No. 6,994,857

Finnegan, Henderson, Farabow,
 Garrett & Dunner, L.L.P.
 901 New York Avenue, N.W.
 Washington, D.C. 20001-4413

MAR 13 2006

<400> 65 cagtctgtgt tgacgcagcc gcc	23
<210> 66	
<211> 23	
<212> DNA	
<213> Artificial Sequence	
<220>	
<221>primer_bind	
<223>Degenerate Jlambda reverse primer useful for amplifying human VL domains	
<400> 66 cagtctgccc tgactcagcc tgc	23
<210> 67	
<211> 23	
<212> DNA	
<213> Artificial Sequence	
<220>	
<221>primer_bind	
<223>Degenerate Jlambda reverse primer useful for amplifying human VL domains	
<400> 67 tcctatgtgc tgactcagcc acc	23
<210> 68	
<211> 23	
<212> DNA	
<213> Artificial Sequence	
<220>	
<221>primer_bind	
<223>Degenerate Jlambda reverse primer useful for amplifying human VL domains	
<400> 68 tcttctgagc tgactcagga ccc	23
<210> 69	
<211> 23	
<212> DNA	
<213> Artificial Sequence	
<220>	
<221>primer_bind	
<223>Degenerate Jlambda reverse primer useful for amplifying human VL domains	
<400> 69 cacgttatac tgactcaacc gcc	23
<210> 70	

MAILING ADDRESS OF SENDER

U.S. Patent No. 6,994,857

Finnegan, Henderson, Farabow,
Garrett & Dunner, L.L.P.
901 New York Avenue, N.W.
Washington, D.C. 20001-4413

MAR 13 2006

<211> 23
 <212> DNA
 <213> Artificial Sequence
 <220>
 <221>primer_bind
 <223>Degenerate Jlambda reverse primer useful for
 amplifying human VL domains

<400> 70
 caggctgtgc tcaactcagcc gtc

23

<210> 71
 <211> 23
 <212> DNA
 <213> Artificial Sequence
 <220>
 <221>primer_bind
 <223>Degenerate Jlambda reverse primer useful for
 amplifying human VL domains

<400> 71
 aattttatgc tgactcagcc cca

23

<210> 72
 <211> 15
 <212> PRT
 <213> Artificial Sequence
 <220>
 <221>turn
 <223>Linker peptide that may be used to join VH
 and VL domains in an scFv.

<400> 72
 Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser
 1 5 10 15

<210> 73
 <211> 23
 <212> PRT
 <213> Homo sapiens

<400> 73
 Cys Cys Cys Ala Ala Gly Ala Ala Thr Thr Cys Cys Cys Thr Thr Ala
 1 5 10 15

Thr Cys Cys Ala Gly Gly Cys
 20

<210> 74
 <211> 429
 <212> PRT

MAILING ADDRESS OF SENDER

U.S. Patent No. 6,994,857

Finnegan, Henderson, Farabow,
 Garrett & Dunner, L.L.P.
 901 New York Avenue, N.W.
 Washington, D.C. 20001-4413

<213> Homo sapiens

<400> 74

Met Cys Pro Gly Ala Leu Trp Val Ala Leu Pro Leu Leu Ser Leu Leu
1 5 10 15
Ala Gly Ser Leu Gln Gly Lys Pro Leu Gln Ser Trp Gly Arg Gly Ser
20 25 30
Ala Gly Gly Asn Ala His Ser Pro Leu Gly Val Pro Gly Gly Gly Leu
35 40 45
Pro Glu His Thr Phe Asn Leu Lys Met Phe Leu Glu Asn Val Lys Val
50 55 60
Asp Phe Leu Arg Ser Leu Asn Leu Ser Gly Val Pro Ser Gln Asp Lys
65 70 75 80
Thr Arg Val Glu Pro Pro Gln Tyr Met Ile Asp Leu Tyr Asn Arg Tyr
85 90 95
Thr Ser Asp Lys Ser Thr Thr Pro Ala Ser Asn Ile Val Arg Ser Phe
100 105 110
Ser Met Glu Asp Ala Ile Ser Ile Thr Ala Thr Glu Asp Phe Pro Phe
115 120 125
Gln Lys His Ile Leu Leu Phe Asn Ile Ser Ile Pro Arg His Glu Gln
130 135 140
Ile Thr Arg Ala Glu Leu Arg Leu Tyr Val Ser Cys Gln Asn His Val
145 150 155 160
Asp Pro Ser His Asp Leu Lys Gly Ser Val Val Ile Tyr Asp Val Leu
165 170 175
Asp Gly Thr Asp Ala Trp Asp Ser Ala Thr Glu Thr Lys Thr Phe Leu
180 185 190
Val Ser Gln Asp Ile Gln Asp Glu Gly Trp Glu Thr Leu Glu Val Ser
195 200 205
Ser Ala Val Lys Arg Trp Val Arg Ser Asp Ser Thr Lys Ser Lys Asn
210 215 220
Lys Leu Glu Val Thr Val Glu Ser His Arg Lys Gly Cys Asp Thr Leu
225 230 235 240
Asp Ile Ser Val Pro Pro Gly Ser Arg Asn Leu Pro Phe Phe Val Val
245 250 255

MAILING ADDRESS OF SENDER

U.S. Patent No. 6,994,857

Finnegan, Henderson, Farabow,
Garrett & Dunner, L.L.P.
901 New York Avenue, N.W.
Washington, D.C. 20001-4413

MAR 13 2006

Phe Ser Asn Asp His Ser Ser Gly Thr Lys Glu Thr Arg Leu Glu Leu
 260 265 270
 Arg Glu Met Ile Ser His Glu Gln Glu Ser Val Leu Lys Lys Leu Ser
 275 280 285
 Lys Asp Gly Ser Thr Glu Ala Gly Glu Ser Ser His Glu Glu Asp Thr
 290 295 300
 Asp Gly His Val Ala Ala Gly Ser Thr Leu Ala Arg Arg Lys Arg Ser
 305 310 315 320
 Ala Gly Ala Gly Ser His Cys Gln Lys Thr Ser Leu Arg Val Asn Phe
 325 330 335
 Glu Asp Ile Gly Trp Asp Ser Trp Ile Ile Ala Pro Lys Glu Tyr Glu
 340 345 350
 Ala Tyr Glu Cys Lys Gly Gly Cys Phe Phe Pro Leu Ala Asp Asp Val
 355 360 365
 Thr Pro Thr Lys His Ala Ile Val Gln Thr Leu Val His Leu Lys Phe
 370 375 380
 Pro Thr Lys Val Gly Lys Ala Cys Cys Val Pro Thr Lys Leu Ser Pro
 385 390 395 400
 Ile Ser Val Leu Tyr Lys Asp Asp Met Gly Val Pro Thr Leu Lys Tyr
 405 410 415
 His Tyr Glu Gly Met Ser Val Ala Glu Cys Gly Cys Arg
 420 425

<210> 75
 <211> 280
 <212> PRT
 <213> Homo sapiens

<400> 75
 Met Ala Pro Ser Gly Ser Leu Ala Val Pro Leu Ala Val Leu Val Leu
 1 5 10 15
 Leu Leu Trp Gly Ala Pro Trp Thr His Gly Arg Arg Ser Asn Val Arg
 20 25 30
 Val Ile Thr Asp Glu Asn Trp Arg Glu Leu Leu Glu Gly Asp Trp Met
 35 40 45
 Ile Glu Phe Tyr Ala Pro Trp Cys Pro Ala Cys Gln Asn Leu Gln Pro
 50 55 60

MAILING ADDRESS OF SENDER

U.S. Patent No. 6,994,857

Finnegan, Henderson, Farabow,
 Garrett & Dunner, L.L.P.
 901 New York Avenue, N.W.
 Washington, D.C. 20001-4413

MAY 18 2006

Glu Trp Glu Ser Phe Ala Glu Trp Gly Glu Asp Leu Glu Val Asn Ile
 65 70 75 80
 Ala Lys Val Asp Val Thr Glu Gln Pro Gly Leu Ser Gly Arg Phe Ile
 85 90 95
 Ile Thr Ala Leu Pro Thr Ile Tyr His Cys Lys Asp Gly Glu Phe Arg
 100 105 110
 Arg Tyr Gln Gly Pro Arg Thr Lys Lys Asp Phe Ile Asn Phe Ile Ser
 115 120 125
 Asp Lys Glu Trp Lys Ser Ile Glu Pro Val Ser Ser Trp Phe Gly Pro
 130 135 140
 Gly Ser Val Leu Met Ser Ser Met Ser Ala Leu Phe Gln Leu Ser Met
 145 150 155 160
 Trp Ile Arg Thr Cys His Asn Tyr Phe Ile Glu Asp Leu Gly Leu Pro
 165 170 175
 Val Trp Gly Ser Tyr Thr Val Phe Ala Leu Ala Thr Leu Phe Ser Gly
 180 185 190
 Leu Leu Leu Gly Leu Cys Met Ile Phe Val Ala Asp Cys Leu Cys Pro
 195 200 205
 Ser Lys Arg Arg Arg Pro Gln Pro Tyr Pro Tyr Pro Ser Lys Lys Leu
 210 215 220
 Leu Ser Glu Ser Ala Gln Pro Leu Lys Lys Val Glu Glu Glu Gln Glu
 225 230 235 240
 Ala Asp Glu Glu Asp Val Ser Glu Glu Glu Ala Glu Ser Lys Glu Gly
 245 250 255
 Thr Asn Lys Asp Phe Pro Gln Asn Ala Ile Arg Gln Arg Ser Leu Gly
 260 265 270
 Pro Ser Leu Ala Thr Asp Lys Ser
 275 280

<210> 76
 <211> 112
 <212> PRT
 <213> Homo sapiens

<400> 76
 Met Phe Trp Val Met Glu Thr Ala Lys Pro Pro Val Ser Glu Asp Ser
 1 5 10 15

MAILING ADDRESS OF SENDER

U.S. Patent No. 6,994,857

Finnegan, Henderson, Farabow,
 Garrett & Dunner, L.L.P.
 901 New York Avenue, N.W.
 Washington, D.C. 20001-4413

MAR 13 2006

Phe Arg Leu Pro Arg Lys Trp Gly Trp Arg Thr Glu Ala Thr Ala Pro
 20 25 30

His Ala Pro Val Pro Gln Ser Ile Cys Pro Arg Tyr Thr Ser Pro Cys
 35 40 45

Ala Pro His Asp Cys Gly Ser Gln Thr Val Gln Gly Asn Ser Leu Ser
 50 55 60

Leu Phe Tyr Thr Leu Ser His Lys Ala Pro Gln Leu Pro His Arg Val
 65 70 75 80

Pro Ala Pro Leu Phe Cys Lys Tyr Val Lys Arg Lys Lys Cys Lys Arg
 85 90 95

Trp Ser Leu Gly Trp Ser Ser Ser Leu Gln Leu Arg Leu Leu Thr Met
 100 105 110

<210> 77

<211> 346

<212> PRT

<213> Homo sapiens

<400> 77

Met Asp Pro Ala Arg Lys Ala Gly Ala Gln Ala Met Ile Trp Thr Ala
 1 5 10 15

Gly Trp Leu Leu Leu Leu Leu Leu Arg Gly Gly Ala Gln Ala Leu Glu
 20 25 30

Cys Tyr Ser Cys Val Gln Lys Ala Asp Asp Gly Cys Ser Pro Asn Lys
 35 40 45

Met Lys Thr Val Lys Cys Ala Pro Gly Val Asp Val Cys Thr Glu Ala
 50 55 60

Val Gly Ala Val Glu Thr Ile His Gly Gln Phe Ser Leu Ala Val Arg
 65 70 75 80

Gly Cys Gly Ser Gly Leu Pro Gly Lys Asn Asp Arg Gly Leu Asp Leu
 85 90 95

His Gly Leu Leu Ala Phe Ile Gln Leu Gln Gln Cys Ala Gln Asp Arg
 100 105 110

Cys Asn Ala Lys Leu Asn Leu Thr Ser Arg Ala Leu Asp Pro Ala Gly
 115 120 125

Asn Glu Ser Ala Tyr Pro Pro Asn Gly Val Glu Cys Tyr Ser Cys Val
 130 135 140

MAILING ADDRESS OF SENDER

U.S. Patent No. 6,994,857

Finnegan, Henderson, Farabow,
 Garrett & Dunner, L.L.P.
 901 New York Avenue, N.W.
 Washington, D.C. 20001-4413

MAR 13 2006

Gly Leu Ser Arg Glu Ala Cys Gln Gly Thr Ser Pro Pro Val Val Ser
 145 150 155 160
 Cys Tyr Asn Ala Ser Asp His Val Tyr Lys Gly Cys Phe Asp Gly Asn
 165 170 175
 Val Thr Leu Thr Ala Ala Asn Val Thr Val Ser Leu Pro Val Arg Gly
 180 185 190
 Cys Val Gln Asp Glu Phe Cys Thr Arg Asp Gly Val Thr Gly Pro Gly
 195 200 205
 Phe Thr Leu Ser Gly Ser Cys Cys Gln Gly Ser Arg Cys Asn Ser Asp
 210 215 220
 Leu Arg Asn Lys Thr Tyr Phe Ser Pro Arg Ile Pro Pro Leu Val Arg
 225 230 235 240
 Leu Pro Pro Pro Glu Pro Thr Thr Val Ala Ser Thr Thr Ser Val Thr
 245 250 255
 Thr Ser Thr Ser Ala Pro Val Arg Pro Thr Ser Thr Thr Lys Pro Met
 260 265 270
 Pro Ala Pro Thr Ser Gln Thr Pro Arg Gln Gly Val Glu His Glu Ala
 275 280 285
 Ser Arg Asp Glu Glu Pro Arg Leu Thr Gly Gly Ala Ala Gly His Gln
 290 295 300
 Asp Arg Ser Asn Ser Gly Gln Tyr Pro Ala Lys Gly Gly Pro Gln Gln
 305 310 315 320
 Pro His Asn Lys Gly Cys Val Ala Pro Thr Ala Gly Leu Ala Ala Leu
 325 330 335
 Leu Leu Ala Val Ala Ala Gly Val Leu Leu
 340 345

<210> 78

<211> 272

<212> PRT

<213> Homo sapiens

<400> 78

Met Lys Gly Lys Lys Gly Ile Val Ala Ala Ser Gly Ser Glu Thr Glu
 1 5 10 15

Asp Glu Asp Ser Met Asp Ile Pro Leu Asp Leu Ser Ser Ser Ala Gly
 20 25 30

MAILING ADDRESS OF SENDER

U.S. Patent No. 6,994,857

Finnegan, Henderson, Farabow,
 Garrett & Dunner, L.L.P.
 901 New York Avenue, N.W.
 Washington, D.C. 20001-4413

MAR 13 2006

Ser Gly Lys Arg Arg Arg Arg Gly Asn Leu Pro Lys Glu Ser Val Gln
 35 40 45
 Ile Leu Arg Asp Trp Leu Tyr Glu His Arg Tyr Asn Ala Tyr Pro Ser
 50 55 60
 Glu Gln Glu Lys Ala Leu Leu Ser Gln Gln Thr His Leu Ser Thr Leu
 65 70 75 80
 Gln Val Cys Asn Trp Phe Ile Asn Ala Arg Arg Arg Leu Leu Pro Asp
 85 90 95
 Met Leu Arg Lys Asp Gly Lys Asp Pro Asn Gln Phe Thr Ile Ser Arg
 100 105 110
 Arg Gly Ala Lys Ile Ser Glu Thr Ser Ser Val Glu Ser Val Met Gly
 115 120 125
 Ile Lys Asn Phe Met Pro Ala Leu Glu Glu Thr Pro Phe His Ser Cys
 130 135 140
 Thr Ala Gly Pro Asn Pro Thr Leu Gly Arg Pro Leu Ser Pro Lys Pro
 145 150 155 160
 Ser Ser Pro Gly Ser Val Leu Ala Arg Pro Ser Val Ile Cys His Thr
 165 170 175
 Thr Val Thr Ala Leu Lys Asp Val Pro Phe Ser Leu Cys Gln Ser Val
 180 185 190
 Gly Val Gly Gln Asn Thr Asp Ile Gln Gln Ile Ala Ala Lys Asn Phe
 195 200 205
 Thr Asp Thr Ser Leu Met Tyr Pro Glu Asp Thr Cys Lys Ser Gly Pro
 210 215 220
 Ser Thr Asn Thr Gln Ser Gly Leu Phe Asn Thr Pro Pro Pro Thr Pro
 225 230 235 240
 Pro Asp Leu Asn Gln Asp Phe Ser Gly Phe Gln Leu Leu Val Asp Val
 245 250 255
 Ala Leu Lys Arg Ala Ala Glu Met Glu Leu Gln Ala Lys Leu Thr Ala
 260 265 270

<210> 79
 <211> 167
 <212> PRT
 <213> Homo sapiens

MAILING ADDRESS OF SENDER

U.S. Patent No. 6,994,857

Finnegan, Henderson, Farabow,
 Garrett & Dunner, L.L.P.
 901 New York Avenue, N.W.
 Washington, D.C. 20001-4413

MAR 13 2006

<400> 79

Met Leu Thr Val Ala Leu Leu Ala Leu Leu Cys Ala Ser Ala Ser Gly
1 5 10 15

Asn Ala Ile Gln Ala Arg Ser Ser Ser Tyr Ser Gly Glu Tyr Gly Gly
20 25 30

Gly Gly Gly Lys Arg Phe Ser His Ser Gly Asn Gln Leu Asp Gly Pro
35 40 45

Ile Thr Ala Leu Arg Val Arg Val Asn Thr Tyr Tyr Ile Val Gly Leu
50 55 60

Gln Val Arg Tyr Gly Lys Val Trp Ser Asp Tyr Val Gly Gly Arg Asn
65 70 75 80

Gly Asp Leu Glu Glu Ile Phe Leu His Pro Gly Glu Ser Val Ile Gln
85 90 95

Val Ser Gly Lys Tyr Lys Trp Tyr Leu Lys Lys Leu Val Phe Val Thr
100 105 110

Asp Lys Gly Arg Tyr Leu Ser Phe Gly Lys Asp Ser Gly Thr Ser Phe
115 120 125

Asn Ala Val Pro Leu His Pro Asn Thr Val Leu Arg Phe Ile Ser Gly
130 135 140

Arg Ser Gly Ser Leu Ile Asp Ala Ile Gly Leu His Trp Asp Val Tyr
145 150 155 160

Pro Thr Ser Cys Ser Arg Cys
165

<210> 80

<211> 22

<212> PRT

<213> Homo sapiens

<220>

<221> SITE

<222> (22)

<223> Xaa equals stop translation

<400> 80

Met Leu Ala Ala Leu Ala Cys Ser Trp Arg Leu Leu Ser Leu Gly Ala
1 5 10 15

His Ser Gly Arg Ala Xaa
20

<210> 81

MAILING ADDRESS OF SENDER

U.S. Patent No. 6,994,857

Finnegan, Henderson, Farabow,
Garrett & Dunner, L.L.P.
901 New York Avenue, N.W.
Washington, D.C. 20001-4413

MAR 13 2006

```

<211> 733
<212> DNA
<213> Homo sapiens

<400> 81
gggatccgga gcccaaattct tctgacaaaa ctcacacatg cccaccgtgc ccagcacctg      60
aattcgaggg tgcaccgtca gtcttctctt tcccccaaa acccaaggac accctcatga      120
tctcccgga tcttgaggtc acatgcgtgg tgggtggacgt aagccacgaa gaccctgagg      180
tcaagttcaa ctggtacgtg gacggcgtgg aggtgcataa tgccaagaca aagccgcggg      240
aggagcagta caacagcacg taccgtgtgg tcagcgtcct caccgtcctg caccaggact      300
ggctgaatgg caaggagtac aagtgcgaagg tctccaacaa agccctccca acccccatcg      360
agaaaacat ctccaaagcc aaagggcagc cccgagaacc acaggtgtac accctgcccc      420
catcccgga tgagctgacc aagaaccagg tcagcctgac ctgcctgggtc aaaggcttct      480
atccaagcga catcgccgtg gagtgggaga gcaatgggca gccggagAAC aactacaaga      540
ccacgcctcc cgtgctggac tccgacggct ccttcttctt ctacagcaag ctcaccgtgg      600
acaagagcag gtggcagcag gggaaagtct tctcatgctc cgtgatgcat gaggctctgc      660
acaaccacta cagcagaag agcctctccc tgtctccggg taaatgagtg cgacggccgc      720
gactctagag gat

<210> 82
<211> 5
<212> PRT
<213> Artificial sequence
<220>
<221> misc_structure
<223> membrane proximal motif of class 1 cytokine receptors

<220>
<221> misc_feature
<222> (3)
<223> Xaa equals any

<400> 82
Trp Ser Xaa Trp Ser
  1             5

<210> 83
<211> 86
<212> DNA

```

MAILING ADDRESS OF SENDER

U.S. Patent No. 6,994,857

Finnegan, Henderson, Farabow,
Garrett & Dunner, L.L.P.
901 New York Avenue, N.W.
Washington, D.C. 20001-4413

MAR 13 2006

```

<213> Artificial Sequence
<220>
<221> primer_bind
<223> forward primer useful for generation of a synthetic gamma
activation site (GAS) containing promoter element

<400> 83
gcgcctcgag atttccccga aatctagatt tccccgaaat gatttccccg aaatgatttc 60

cccgaatat ctgccatctc aattag 86

<210> 84
<211> 27
<212> DNA
<213> Artificial Sequence
<220>
<221> primer_bind
<223> reverse primer useful for generation of a synthetic gamma
activation site (GAS) containing promoter element

<400> 84
gcggcaagct ttttgcaaag cctagggc 27

<210> 85
<211> 271
<212> DNA
<213> Artificial Sequence
<220>
<221> misc_feature
<223> Synthetic GAS-SV40 promoter sequence

<400> 85
ctcgagattt ccccgaatc tagatttccc cgaaatgatt tccccgaaat gatttccccg 60

aaatatctgc catctcaatt agtcagcaac catagtcccc cccctaactc cgcccatccc 120

gcccctaact ccgcccagtt ccgcccattc tccgcccatt ggctgactaa ttttttttat 180

ttatgcagag gccgaggccg cctcggcctc tgagctattc cagaagtagt gaggaggctt 240

ttttggaggc ctaggctttt gcaaaaagct t 271

<210> 86
<211> 32
<212> DNA
<213> Artificial Sequence
<220>
<221> primer_bind
<223> primer useful for generation of a EGR/SEAP reporter construct

<400> 86

```

MAILING ADDRESS OF SENDER

U.S. Patent No. 6,994,857

Finnegan, Henderson, Farabow,
Garrett & Dunner, L.L.P.
901 New York Avenue, N.W.
Washington, D.C. 20001-4413

MAR 13 2000

gcgctcgagg gatgacagcg atagaacccc gg 32

<210> 87
 <211> 31
 <212> DNA
 <213> Artificial Sequence
 <220>
 <221> primer_bind
 <223> primer useful for generation of a EGR/SEAP reporter construct

<400> 87
 gcgaagcttc gcgactcccc ggatccgcct c 31

<210> 88
 <211> 12
 <212> DNA
 <213> Artificial Sequence
 <220>
 <221> misc_binding
 <223> NF-KB binding site

<400> 88
 ggggactttc cc 12

<210> 89
 <211> 73
 <212> DNA
 <213> Artificial Sequence
 <220>
 <221> primer_bind
 <223> forward primer useful for generation of a vector containing the
 NF-KB promoter element

<400> 89
 gcggcctcga ggggactttc ccggggactt tccggggact ttccgggact ttccatcctg 60

ccatctcaat tag 73

<210> 90
 <211> 256
 <212> DNA
 <213> Artificial Sequence
 <220>
 <221> misc_feature
 <223> Synthetic NF-KB/SV40 promoter

<400> 90
 ctcgagggga ctttcccgga gactttccgg ggactttccg ggactttcca tctgccatct 60

caattagtca gcaaccatag tccgcgccct aactccgccc atcccgcgcc taactccgcc 120

cagttccgcc cattctccgc cccatggctg actaattttt tttatttatg cagaggccga 180

MAILING ADDRESS OF SENDER

U.S. Patent No. 6,994,857

Finnegan, Henderson, Farabow,
 Garrett & Dunner, L.L.P.
 901 New York Avenue, N.W.
 Washington, D.C. 20001-4413

MAR 13 2006

ggccgctcg gcctctgagc tattccagaa gtagtgagga ggcttttttg gaggcctagg 240

cttttgcaaa aagctt 256

In the Claims

Col. 313, line 22, in claim 1(c), "amino and" should read -- amino --.

Col. 313, line 33, in claim 1(e), "or fragment thereof and albumin" should read -- or fragment thereof, and albumin --.

Col. 313, line 55, in claim 1(i), "proten" should read -- protein --.

Col. 316, line 17, in claim 22, "protein, or thereof" should read -- protein, or fragment thereof --.

MAILING ADDRESS OF SENDER

U.S. Patent No. 6,994,857

Finnegan, Henderson, Farabow,
Garrett & Dunner, L.L.P.
901 New York Avenue, N.W.
Washington, D.C. 20001-4413

MAR 13 2006